[
  {
    "id": "ems-epinephrine-pediatric-dosing",
    "title": "Epinephrine Pediatric Color Code Dosing - EXACT VALUES",
    "category": "Medication",
    "keywords": ["epinephrine", "epi", "pediatric", "color", "code", "dosing", "exact", "grey", "pink", "red", "purple", "yellow", "white", "blue", "orange", "green", "3kg", "4kg", "5kg", "6kg", "7kg", "8kg", "9kg", "10kg", "11kg", "12kg", "13kg", "14kg", "15kg", "16kg", "17kg", "18kg", "19kg", "20kg", "22kg", "24kg", "26kg", "28kg", "30kg", "32kg", "34kg", "36kg", "1 1000", "cardiac", "arrest", "vital", "signs", "cardioversion", "defibrillation", "joules", "airway", "supraglottic", "igel", "gastric", "suction", "adenosine", "albuterol", "amiodarone", "atropine", "calcium", "chloride", "dextrose", "diphenhydramine", "duodote", "fentanyl", "glucagon", "hydroxocobalamin", "lidocaine", "midazolam", "morphine", "naloxone", "normal", "saline", "sodium", "bicarbonate", "ketorolac", "ondansetron", "glucopaste"],
    "content": "**PEDIATRIC COLOR CODE DOSING - EXACT VALUES FROM SCREENSHOTS**\n\n**PURPLE 10KG COMPREHENSIVE DATA - EXACT VALUES **\n- **Weight ** 10 kg\n- **Length ** 73-78 cm\n- **Age ** 11-14 months\n- **Color Code ** Purple\n\n**NORMAL VITAL SIGNS **\n- **Heart Rate ** 90-140 bpm\n- **Respirations ** 24-40 bpm\n- **Systolic BP ** >70 mmHg\n\n**CARDIOVERSION/DEFIBRILLATION SETTINGS **\n- **10kg Purple Cardioversion ** 10 joules , 20 joules \n- **10kg Purple Defibrillation ** 20 joules , 40 joules \n\n**AIRWAY MANAGEMENT **\n- **Supraglottic Airway ** igel Size 1.5\n- **Gastric Suction Catheter ** 10 F\n\n**COMPREHENSIVE MEDICATION DOSING - PURPLE 10KG **\n- **Adenosine ** 1 mg  rapid IV push\n- **Albuterol NEB ** 2.5 mg \n- **Amiodarone ** 50 mg \n- **Atropine ** 0.2 mg \n- **Calcium Chloride ** 200 mg  - Dilute 1 1 with NS\n- **Dextrose 10% slow IV ** 50 mL \n- **Diphenhydramine IV/IM ** 10 mg \n- **DuoDote™ ** 1 dose\n- **Epinephrine Push Dose ** 10 mcg \n- **Epinephrine 0.1mg/mL IV ** 0.1 mg \n- **Epinephrine 1mg/mL IM ** 0.1 mg \n- **Epinephrine 1mg/mL NEB ** 5 mg \n- **Fentanyl IV/IM ** 10 mcg \n- **Fentanyl IN ** 15 mcg \n- **Glucagon IM ** 1 mg \n- **Hydroxocobalamin IV/IO ** 700 mg  - Reconstitute 5g vial in 200ml NS\n- **Lidocaine 2% IO ** 5 mg \n- **Midazolam Agitation/Sedation IV/IO ** 1 mg \n- **Midazolam Agitation/Sedation IN/IM ** 2 mg \n- **Midazolam Seizure 0-11mo IN/IM ** 2 mg \n- **Midazolam Seizure ≥12mo IN/IM ** PediDOSE\n- **Morphine IV/IM/IO ** 1 mg \n- **Naloxone IV/IM/IN ** 1 mg \n- **Normal Saline IV Bolus ** 200 mL \n- **Sodium Bicarbonate ** 10 mEq  - Dilute 1 1 with NS\n\n**PURPLE 11KG COMPREHENSIVE DATA - EXACT VALUES **\n- **Weight ** 11 kg\n- **Length ** 78-83 cm\n- **Age ** 15-18 months\n- **Color Code ** Purple\n\n**NORMAL VITAL SIGNS **\n- **Heart Rate ** 90-140 bpm\n- **Respirations ** 24-40 bpm\n- **Systolic BP ** >70 mmHg\n\n**CARDIOVERSION/DEFIBRILLATION SETTINGS **\n- **11kg Purple Cardioversion ** 11 joules , 22 joules \n- **11kg Purple Defibrillation ** 22 joules , 44 joules \n\n**AIRWAY MANAGEMENT **\n- **Supraglottic Airway ** igel Size 1.5\n- **Gastric Suction Catheter ** 10 F\n\n**COMPREHENSIVE MEDICATION DOSING - PURPLE 11KG **\n- **Adenosine ** 1.1 mg  rapid IV push\n- **Albuterol NEB ** 2.5 mg \n- **Amiodarone ** 55 mg \n- **Atropine ** 0.22 mg \n- **Calcium Chloride ** 220 mg  - Dilute 1 1 with NS\n- **Dextrose 10% slow IV ** 55 mL \n- **Diphenhydramine IV/IM ** 11 mg \n- **DuoDote™ ** 1 dose\n- **Epinephrine Push Dose ** 10 mcg \n- **Epinephrine 0.1mg/mL IV ** 0.11 mg \n- **Epinephrine 1mg/mL IM ** 0.11 mg \n- **Epinephrine 1mg/mL NEB ** 5 mg \n- **Fentanyl IV/IM ** 11 mcg \n- **Fentanyl IN ** 16.5 mcg \n- **Glucagon IM ** 1 mg \n- **Hydroxocobalamin IV/IO ** 770 mg  - Reconstitute 5g vial in 200ml NS\n- **Lidocaine 2% IO ** 5.5 mg \n- **Midazolam Agitation/Sedation IV/IO ** 1.1 mg \n- **Midazolam Agitation/Sedation IN/IM ** 2.2 mg \n- **Midazolam Seizure 0-11mo IN/IM ** 2.2 mg \n- **Midazolam Seizure ≥12mo IN/IM ** PediDOSE\n- **Morphine IV/IM/IO ** 1.1 mg \n- **Naloxone IV/IM/IN ** 1.1 mg \n- **Normal Saline IV Bolus ** 220 mL \n- **Sodium Bicarbonate ** 11 mEq  - Dilute 1 1 with NS\n\n**YELLOW 12KG COMPREHENSIVE DATA - EXACT VALUES **\n- **Weight ** 12 kg\n- **Length ** 83-94.5 cm\n- **Age ** 19-35 months\n- **Color Code ** Yellow\n\n**NORMAL VITAL SIGNS **\n- **Heart Rate ** 90-140 bpm\n- **Respirations ** 20-30 bpm\n- **Systolic BP ** >70 mmHg\n\n**CARDIOVERSION/DEFIBRILLATION SETTINGS **\n- **12kg Yellow Cardioversion ** 12 joules , 24 joules \n- **12kg Yellow Defibrillation ** 24 joules , 48 joules \n\n**AIRWAY MANAGEMENT **\n- **Supraglottic Airway ** igel Size 2\n- **Gastric Suction Catheter ** 12 F\n\n**COMPREHENSIVE MEDICATION DOSING - YELLOW 12KG **\n- **Adenosine ** 1.2 mg  rapid IV push\n- **Albuterol NEB ** 2.5 mg \n- **Amiodarone ** 60 mg \n- **Atropine ** 0.24 mg \n- **Calcium Chloride ** 240 mg  - Dilute 1 1 with NS\n- **Dextrose 10% slow IV ** 60 mL \n- **Diphenhydramine IV/IM ** 12 mg \n- **DuoDote™ ** 1 dose\n- **Epinephrine Push Dose ** 10 mcg \n- **Epinephrine 0.1mg/mL IV ** 0.12 mg \n- **Epinephrine 1mg/mL IM ** 0.12 mg \n- **Epinephrine 1mg/mL NEB ** 5 mg \n- **Fentanyl IV/IM ** 12 mcg \n- **Fentanyl IN ** 18 mcg \n- **Glucagon IM ** 1 mg \n- **Hydroxocobalamin IV/IO ** 840 mg  - Reconstitute 5g vial in 200ml NS\n- **Lidocaine 2% IO ** 6 mg \n- **Midazolam Agitation/Sedation IV/IO ** 1.2 mg \n- **Midazolam Agitation/Sedation IN/IM ** 2.4 mg \n- **Midazolam Seizure ≥12mo IN/IM ** PediDOSE\n- **Morphine IV/IM/IO ** 1.2 mg \n- **Naloxone IV/IM/IN ** 1.2 mg \n- **Normal Saline IV Bolus ** 240 mL \n- **Sodium Bicarbonate ** 12 mEq  - Dilute 1 1 with NS\n\n**YELLOW 13KG COMPREHENSIVE DATA - EXACT VALUES **\n- **Weight ** 13 kg\n- **Length ** 83-94.5 cm\n- **Age ** 19-35 months\n- **Color Code ** Yellow\n\n**NORMAL VITAL SIGNS **\n- **Heart Rate ** 90-140 bpm\n- **Respirations ** 20-30 bpm\n- **Systolic BP ** >70 mmHg\n\n**CARDIOVERSION/DEFIBRILLATION SETTINGS **\n- **13kg Yellow Cardioversion ** 13 joules , 26 joules \n- **13kg Yellow Defibrillation ** 26 joules , 52 joules \n\n**AIRWAY MANAGEMENT **\n- **Supraglottic Airway ** igel Size 2\n- **Gastric Suction Catheter ** 12 F\n\n**COMPREHENSIVE MEDICATION DOSING - YELLOW 13KG **\n- **Adenosine ** 1.3 mg  rapid IV push\n- **Albuterol NEB ** 2.5 mg \n- **Amiodarone ** 65 mg \n- **Atropine ** 0.26 mg \n- **Calcium Chloride ** 260 mg  - Dilute 1 1 with NS\n- **Dextrose 10% slow IV ** 65 mL \n- **Diphenhydramine IV/IM ** 13 mg \n- **DuoDote™ ** 1 dose\n- **Epinephrine Push Dose ** 10 mcg \n- **Epinephrine 0.1mg/mL IV ** 0.13 mg \n- **Epinephrine 1mg/mL IM ** 0.13 mg \n- **Epinephrine 1mg/mL NEB ** 5 mg \n- **Fentanyl IV/IM ** 13 mcg \n- **Fentanyl IN ** 19.5 mcg \n- **Glucagon IM ** 1 mg \n- **Hydroxocobalamin IV/IO ** 910 mg  - Reconstitute 5g vial in 200ml NS\n- **Lidocaine 2% IO ** 6.5 mg \n- **Midazolam Agitation/Sedation IV/IO ** 1.3 mg \n- **Midazolam Agitation/Sedation IN/IM ** 2.6 mg \n- **Midazolam Seizure ≥12mo IN/IM ** PediDOSE\n- **Morphine IV/IM/IO ** 1.3 mg \n- **Naloxone IV/IM/IN ** 1.3 mg \n- **Normal Saline IV Bolus ** 260 mL \n- **Sodium Bicarbonate ** 13 mEq  - Dilute 1 1 with NS\n\n**YELLOW 14KG COMPREHENSIVE DATA - EXACT VALUES **\n- **Weight ** 14 kg\n- **Length ** 83-94.5 cm\n- **Age ** 19-35 months\n- **Color Code ** Yellow\n\n**NORMAL VITAL SIGNS **\n- **Heart Rate ** 90-140 bpm\n- **Respirations ** 20-30 bpm\n- **Systolic BP ** >70 mmHg\n\n**CARDIOVERSION/DEFIBRILLATION SETTINGS **\n- **14kg Yellow Cardioversion ** 14 joules , 28 joules \n- **14kg Yellow Defibrillation ** 28 joules , 56 joules \n\n**AIRWAY MANAGEMENT **\n- **Supraglottic Airway ** igel Size 2\n- **Gastric Suction Catheter ** 12 F\n\n**COMPREHENSIVE MEDICATION DOSING - YELLOW 14KG **\n- **Adenosine ** 1.4 mg  rapid IV push\n- **Albuterol NEB ** 2.5 mg \n- **Amiodarone ** 70 mg \n- **Atropine ** 0.28 mg \n- **Calcium Chloride ** 280 mg  - Dilute 1 1 with NS\n- **Dextrose 10% slow IV ** 70 mL \n- **Diphenhydramine IV/IM ** 14 mg \n- **DuoDote™ ** 1 dose\n- **Epinephrine Push Dose ** 10 mcg \n- **Epinephrine 0.1mg/mL IV ** 0.14 mg \n- **Epinephrine 1mg/mL IM ** 0.14 mg \n- **Epinephrine 1mg/mL NEB ** 5 mg \n- **Fentanyl IV/IM ** 14 mcg \n- **Fentanyl IN ** 21 mcg \n- **Glucagon IM ** 1 mg \n- **Hydroxocobalamin IV/IO ** 980 mg  - Reconstitute 5g vial in 200ml NS\n- **Lidocaine 2% IO ** 7 mg \n- **Midazolam Agitation/Sedation IV/IO ** 1.4 mg \n- **Midazolam Agitation/Sedation IN/IM ** 2.8 mg \n- **Midazolam Seizure ≥12mo IN/IM ** PediDOSE\n- **Morphine IV/IM/IO ** 1.4 mg \n- **Naloxone IV/IM/IN ** 1.4 mg \n- **Normal Saline IV Bolus ** 280 mL \n- **Sodium Bicarbonate ** 14 mEq  - Dilute 1 1 with NS\n\n**WHITE 15KG COMPREHENSIVE DATA - EXACT VALUES **\n- **Weight ** 15 kg\n- **Length ** 94.5-107 cm\n- **Age ** 3-4 years\n- **Color Code ** White\n\n**NORMAL VITAL SIGNS **\n- **Heart Rate ** 80-130 bpm\n- **Respirations ** 20-30 bpm\n- **Systolic BP ** >75 mmHg\n\n**CARDIOVERSION/DEFIBRILLATION SETTINGS **\n- **15kg White Cardioversion ** 15 joules , 30 joules \n- **15kg White Defibrillation ** 30 joules , 60 joules \n\n**AIRWAY MANAGEMENT **\n- **Supraglottic Airway ** igel Size 2\n- **Gastric Suction Catheter ** 12 F\n\n**COMPREHENSIVE MEDICATION DOSING - WHITE 15KG **\n- **Adenosine ** 1.5 mg  rapid IV push\n- **Albuterol NEB <4 years ** 2.5 mg \n- **Albuterol NEB ≥4 years ** 5 mg \n- **Amiodarone ** 75 mg \n- **Atropine ** 0.3 mg \n- **Calcium Chloride ** 300 mg  - Dilute 1 1 with NS\n- **Dextrose 10% slow IV ** 75 mL \n- **Diphenhydramine IV/IM ** 15 mg \n- **DuoDote™ ** 1 dose\n- **Epinephrine Push Dose ** 10 mcg \n- **Epinephrine 0.1mg/mL IV ** 0.15 mg \n- **Epinephrine 1mg/mL IM ** 0.15 mg \n- **Epinephrine 1mg/mL NEB ** 5 mg \n- **Fentanyl IV/IM ** 15 mcg \n- **Fentanyl IN ** 22.5 mcg \n- **Glucagon IM ** 1 mg \n- **Glucopaste  ** 15 gm \n- **Hydroxocobalamin IV/IO ** 1050 mg  - Reconstitute 5g vial in 200ml NS\n- **Ketorolac slow IV/IO  ** 7.5 mg \n- **Ketorolac IM  ** 7.5 mg \n- **Lidocaine 2% IO ** 7.5 mg \n- **Midazolam Agitation/Sedation IV/IO ** 1.5 mg \n- **Midazolam Agitation/Sedation IN/IM ** 3 mg \n- **Midazolam Seizure ≥12mo IN/IM ** PediDOSE\n- **Morphine IV/IM/IO ** 1.5 mg \n- **Naloxone IV/IM/IN ** 1.5 mg \n- **Normal Saline IV Bolus ** 300 mL \n- **Ondansetron ODT  ** 4 mg \n- **Sodium Bicarbonate ** 15 mEq  - Dilute 1 1 with NS\n\n**WHITE 16KG COMPREHENSIVE DATA - EXACT VALUES **\n- **Weight ** 16 kg\n- **Length ** 94.5-107 cm\n- **Age ** 3-4 years\n- **Color Code ** White\n\n**NORMAL VITAL SIGNS **\n- **Heart Rate ** 80-130 bpm\n- **Respirations ** 20-30 bpm\n- **Systolic BP ** >75 mmHg\n\n**CARDIOVERSION/DEFIBRILLATION SETTINGS **\n- **16kg White Cardioversion ** 16 joules , 32 joules \n- **16kg White Defibrillation ** 32 joules , 64 joules \n\n**AIRWAY MANAGEMENT **\n- **Supraglottic Airway ** igel Size 2\n- **Gastric Suction Catheter ** 12 F\n\n**COMPREHENSIVE MEDICATION DOSING - WHITE 16KG **\n- **Adenosine ** 1.6 mg  rapid IV push\n- **Albuterol NEB <4 years ** 2.5 mg \n- **Albuterol NEB ≥4 years ** 5 mg \n- **Amiodarone ** 80 mg \n- **Atropine ** 0.32 mg \n- **Calcium Chloride ** 320 mg  - Dilute 1 1 with NS\n- **Dextrose 10% slow IV ** 80 mL \n- **Diphenhydramine IV/IM ** 16 mg \n- **DuoDote™ ** 1 dose\n- **Epinephrine Push Dose ** 10 mcg \n- **Epinephrine 0.1mg/mL IV ** 0.16 mg \n- **Epinephrine 1mg/mL IM ** 0.16 mg \n- **Epinephrine 1mg/mL NEB ** 5 mg \n- **Fentanyl IV/IM ** 16 mcg \n- **Fentanyl IN ** 24 mcg \n- **Glucagon IM ** 1 mg \n- **Glucopaste  ** 15 gm \n- **Hydroxocobalamin IV/IO ** 1120 mg  - Reconstitute 5g vial in 200ml NS\n- **Ketorolac slow IV/IO  ** 8 mg \n- **Ketorolac IM  ** 8 mg \n- **Lidocaine 2% IO ** 8 mg \n- **Midazolam Agitation/Sedation IV/IO ** 1.6 mg \n- **Midazolam Agitation/Sedation IN/IM ** 3.2 mg \n- **Midazolam Seizure ≥12mo IN/IM ** PediDOSE\n- **Morphine IV/IM/IO ** 1.6 mg \n- **Naloxone IV/IM/IN ** 1.6 mg \n- **Normal Saline IV Bolus ** 320 mL \n- **Ondansetron ODT  ** 4 mg \n- **Sodium Bicarbonate ** 16 mEq  - Dilute 1 1 with NS\n\n**WHITE 17KG COMPREHENSIVE DATA - EXACT VALUES **\n- **Weight ** 17 kg\n- **Length ** 94.5-107 cm\n- **Age ** 3-4 years\n- **Color Code ** White\n\n**NORMAL VITAL SIGNS **\n- **Heart Rate ** 80-130 bpm\n- **Respirations ** 20-30 bpm\n- **Systolic BP ** >75 mmHg\n\n**CARDIOVERSION/DEFIBRILLATION SETTINGS **\n- **17kg White Cardioversion ** 17 joules , 34 joules \n- **17kg White Defibrillation ** 34 joules , 68 joules \n\n**AIRWAY MANAGEMENT **\n- **Supraglottic Airway ** igel Size 2\n- **Gastric Suction Catheter ** 12 F\n\n**COMPREHENSIVE MEDICATION DOSING - WHITE 17KG **\n- **Adenosine ** 1.7 mg  rapid IV push\n- **Albuterol NEB <4 years ** 2.5 mg \n- **Albuterol NEB ≥4 years ** 5 mg \n- **Amiodarone ** 85 mg \n- **Atropine ** 0.34 mg \n- **Calcium Chloride ** 340 mg  - Dilute 1 1 with NS\n- **Dextrose 10% slow IV ** 85 mL \n- **Diphenhydramine IV/IM ** 17 mg \n- **DuoDote™ ** 1 dose\n- **Epinephrine Push Dose ** 10 mcg \n- **Epinephrine 0.1mg/mL IV ** 0.17 mg \n- **Epinephrine 1mg/mL IM ** 0.17 mg \n- **Epinephrine 1mg/mL NEB ** 5 mg \n- **Fentanyl IV/IM ** 17 mcg \n- **Fentanyl IN ** 25.5 mcg \n- **Glucagon IM ** 1 mg \n- **Glucopaste  ** 15 gm \n- **Hydroxocobalamin IV/IO ** 1190 mg  - Reconstitute 5g vial in 200ml NS\n- **Ketorolac slow IV/IO  ** 8.5 mg \n- **Ketorolac IM  ** 8.5 mg \n- **Lidocaine 2% IO ** 8.5 mg \n- **Midazolam Agitation/Sedation IV/IO ** 1.7 mg \n- **Midazolam Agitation/Sedation IN/IM ** 3.4 mg \n- **Midazolam Seizure ≥12mo IN/IM ** PediDOSE\n- **Morphine IV/IM/IO ** 1.7 mg \n- **Naloxone IV/IM/IN ** 1.7 mg \n- **Normal Saline IV Bolus ** 340 mL \n- **Ondansetron ODT  ** 4 mg \n- **Sodium Bicarbonate ** 17 mEq  - Dilute 1 1 with NS\n\n**WHITE 18KG COMPREHENSIVE DATA - EXACT VALUES **\n- **Weight ** 18 kg\n- **Length ** 94.5-107 cm\n- **Age ** 3-4 years\n- **Color Code ** White\n\n**NORMAL VITAL SIGNS **\n- **Heart Rate ** 80-130 bpm\n- **Respirations ** 20-30 bpm\n- **Systolic BP ** >75 mmHg\n\n**CARDIOVERSION/DEFIBRILLATION SETTINGS **\n- **18kg White Cardioversion ** 18 joules , 36 joules \n- **18kg White Defibrillation ** 36 joules , 72 joules \n\n**AIRWAY MANAGEMENT **\n- **Supraglottic Airway ** igel Size 2\n- **Gastric Suction Catheter ** 12 F\n\n**COMPREHENSIVE MEDICATION DOSING - WHITE 18KG **\n- **Adenosine ** 1.8 mg  rapid IV push\n- **Albuterol NEB <4 years ** 2.5 mg \n- **Albuterol NEB ≥4 years ** 5 mg \n- **Amiodarone ** 90 mg \n- **Atropine ** 0.36 mg \n- **Calcium Chloride ** 360 mg  - Dilute 1 1 with NS\n- **Dextrose 10% slow IV ** 90 mL \n- **Diphenhydramine IV/IM ** 18 mg \n- **DuoDote™ ** 1 dose\n- **Epinephrine Push Dose ** 10 mcg \n- **Epinephrine 0.1mg/mL IV ** 0.18 mg \n- **Epinephrine 1mg/mL IM ** 0.18 mg \n- **Epinephrine 1mg/mL NEB ** 5 mg \n- **Fentanyl IV/IM ** 18 mcg \n- **Fentanyl IN ** 27 mcg \n- **Glucagon IM ** 1 mg \n- **Glucopaste  ** 15 gm \n- **Hydroxocobalamin IV/IO ** 1260 mg  - Reconstitute 5g vial in 200ml NS\n- **Ketorolac slow IV/IO  ** 9 mg \n- **Ketorolac IM  ** 9 mg \n- **Lidocaine 2% IO ** 9 mg \n- **Midazolam Agitation/Sedation IV/IO ** 1.8 mg \n- **Midazolam Agitation/Sedation IN/IM ** 3.6 mg \n- **Midazolam Seizure ≥12mo IN/IM ** PediDOSE\n- **Morphine IV/IM/IO ** 1.8 mg \n- **Naloxone IV/IM/IN ** 1.8 mg \n- **Normal Saline IV Bolus ** 360 mL \n- **Ondansetron ODT  ** 4 mg \n- **Sodium Bicarbonate ** 18 mEq  - Dilute 1 1 with NS\n\n**BLUE 19KG COMPREHENSIVE DATA - EXACT VALUES **\n- **Weight ** 19 kg\n- **Length ** 107-119.5 cm\n- **Age ** 5-6 years\n- **Color Code ** Blue\n\n**NORMAL VITAL SIGNS **\n- **Heart Rate ** 70-120 bpm\n- **Respirations ** 15-30 bpm\n- **Systolic BP ** >80 mmHg\n\n**CARDIOVERSION/DEFIBRILLATION SETTINGS **\n- **19kg Blue Cardioversion ** 19 joules , 38 joules \n- **19kg Blue Defibrillation ** 38 joules , 76 joules \n\n**AIRWAY MANAGEMENT **\n- **Supraglottic Airway ** igel Size 2\n- **Gastric Suction Catheter ** 12 F\n\n**COMPREHENSIVE MEDICATION DOSING - BLUE 19KG **\n- **Adenosine ** 1.9 mg  rapid IV push\n- **Albuterol NEB ** 5 mg \n- **Amiodarone ** 95 mg \n- **Atropine ** 0.38 mg \n- **Calcium Chloride ** 380 mg  - Dilute 1 1 with NS\n- **Dextrose 10% slow IV ** 95 mL \n- **Diphenhydramine IV/IM ** 19 mg \n- **DuoDote™ ** 1 dose\n- **Epinephrine Push Dose ** 10 mcg \n- **Epinephrine 0.1mg/mL IV ** 0.19 mg \n- **Epinephrine 1mg/mL IM ** 0.19 mg \n- **Epinephrine 1mg/mL NEB ** 5 mg \n- **Fentanyl IV/IM ** 19 mcg \n- **Fentanyl IN ** 28.5 mcg \n- **Glucagon IM ** 1 mg \n- **Glucopaste ** 15 gm \n- **Hydroxocobalamin IV/IO ** 1330 mg  - Reconstitute 5g vial in 200ml NS\n- **Ketorolac slow IV/IO ** 9.5 mg \n- **Ketorolac IM ** 9.5 mg \n- **Lidocaine 2% IO ** 9.5 mg \n- **Midazolam Agitation/Sedation IV/IO ** 1.9 mg \n- **Midazolam Agitation/Sedation IN/IM ** 3.8 mg \n- **Midazolam Seizure ≥12mo IN/IM ** PediDOSE\n- **Morphine IV/IM/IO ** 1.9 mg \n- **Naloxone IV/IM/IN ** 1.9 mg \n- **Normal Saline IV Bolus ** 380 mL \n- **Ondansetron ODT ** 4 mg \n- **Sodium Bicarbonate ** 19 mEq  - Dilute 1 1 with NS\n\n**BLUE 20KG COMPREHENSIVE DATA - EXACT VALUES **\n- **Weight ** 20 kg\n- **Length ** 107-119.5 cm\n- **Age ** 5-6 years\n- **Color Code ** Blue\n\n**NORMAL VITAL SIGNS **\n- **Heart Rate ** 70-120 bpm\n- **Respirations ** 15-30 bpm\n- **Systolic BP ** >80 mmHg\n\n**CARDIOVERSION/DEFIBRILLATION SETTINGS **\n- **20kg Blue Cardioversion ** 20 joules , 40 joules \n- **20kg Blue Defibrillation ** 40 joules , 80 joules \n\n**AIRWAY MANAGEMENT **\n- **Supraglottic Airway ** igel Size 2\n- **Gastric Suction Catheter ** 12 F\n\n**COMPREHENSIVE MEDICATION DOSING - BLUE 20KG **\n- **Adenosine ** 2 mg  rapid IV push\n- **Albuterol NEB ** 5 mg \n- **Amiodarone ** 100 mg \n- **Atropine ** 0.4 mg \n- **Calcium Chloride ** 400 mg  - Dilute 1 1 with NS\n- **Dextrose 10% slow IV ** 100 mL \n- **Diphenhydramine IV/IM ** 20 mg \n- **DuoDote™ ** 1 dose\n- **Epinephrine Push Dose ** 10 mcg \n- **Epinephrine 0.1mg/mL IV ** 0.2 mg \n- **Epinephrine 1mg/mL IM ** 0.2 mg \n- **Epinephrine 1mg/mL NEB ** 5 mg \n- **Fentanyl IV/IM ** 20 mcg \n- **Fentanyl IN ** 30 mcg \n- **Glucagon IM ** 1 mg \n- **Glucopaste ** 15 gm \n- **Hydroxocobalamin IV/IO ** 1400 mg  - Reconstitute 5g vial in 200ml NS\n- **Ketorolac slow IV/IO ** 10 mg \n- **Ketorolac IM ** 10 mg \n- **Lidocaine 2% IO ** 10 mg \n- **Midazolam Agitation/Sedation IV/IO ** 2 mg \n- **Midazolam Agitation/Sedation IN/IM ** 4 mg \n- **Midazolam Seizure ≥12mo IN/IM ** PediDOSE\n- **Morphine IV/IM/IO ** 2 mg \n- **Naloxone IV/IM/IN ** 2 mg \n- **Normal Saline IV Bolus ** 400 mL \n- **Ondansetron ODT ** 4 mg \n- **Sodium Bicarbonate ** 20 mEq  - Dilute 1 1 with NS\n\n**BLUE 22KG COMPREHENSIVE DATA - EXACT VALUES **\n- **Weight ** 22 kg\n- **Length ** 107-119.5 cm\n- **Age ** 5-6 years\n- **Color Code ** Blue\n\n**NORMAL VITAL SIGNS **\n- **Heart Rate ** 70-120 bpm\n- **Respirations ** 15-30 bpm\n- **Systolic BP ** >80 mmHg\n\n**CARDIOVERSION/DEFIBRILLATION SETTINGS **\n- **22kg Blue Cardioversion ** 22 joules , 44 joules \n- **22kg Blue Defibrillation ** 44 joules , 88 joules \n\n**AIRWAY MANAGEMENT **\n- **Supraglottic Airway ** igel Size 2\n- **Gastric Suction Catheter ** 12 F\n\n**COMPREHENSIVE MEDICATION DOSING - BLUE 22KG **\n- **Adenosine ** 2.2 mg  rapid IV push\n- **Albuterol NEB ** 5 mg \n- **Amiodarone ** 110 mg \n- **Atropine ** 0.44 mg \n- **Calcium Chloride ** 440 mg  - Dilute 1 1 with NS\n- **Dextrose 10% slow IV ** 110 mL \n- **Diphenhydramine IV/IM ** 22 mg \n- **DuoDote™ ** 1 dose\n- **Epinephrine Push Dose ** 10 mcg \n- **Epinephrine 0.1mg/mL IV ** 0.22 mg \n- **Epinephrine 1mg/mL IM ** 0.22 mg \n- **Epinephrine 1mg/mL NEB ** 5 mg \n- **Fentanyl IV/IM ** 22 mcg \n- **Fentanyl IN ** 33 mcg \n- **Glucagon IM ** 1 mg \n- **Glucopaste ** 15 gm \n- **Hydroxocobalamin IV/IO ** 1540 mg  - Reconstitute 5g vial in 200ml NS\n- **Ketorolac slow IV/IO ** 11 mg \n- **Ketorolac IM ** 11 mg \n- **Lidocaine 2% IO ** 11 mg \n- **Midazolam Agitation/Sedation IV/IO ** 2.2 mg \n- **Midazolam Agitation/Sedation IN/IM ** 4.4 mg \n- **Midazolam Seizure ≥12mo IN/IM ** PediDOSE\n- **Morphine IV/IM/IO ** 2.2 mg \n- **Naloxone IV/IM/IN ** 2 mg \n- **Normal Saline IV Bolus ** 440 mL \n- **Ondansetron ODT ** 4 mg \n- **Sodium Bicarbonate ** 22 mEq  - Dilute 1 1 with NS\n\n**EPINEPHRINE  - EXACT DOSING **\n- **Grey 3kg Epi 1 1000 ** 0.03 mg  IM\n- **Grey 4kg Epi 1 1000 ** 0.04 mg  IM\n- **Grey 5kg Epi 1 1000 ** 0.05 mg  IM\n- **Pink 6kg Epi 1 1000 ** 0.06 mg  IM\n- **Pink 7kg Epi 1 1000 ** 0.07 mg  IM\n- **Red 8kg Epi 1 1000 ** 0.08 mg  IM\n- **Red 9kg Epi 1 1000 ** 0.09 mg  IM\n- **Purple 10kg Epi 1 1000 ** 0.1 mg  IM\n- **Purple 11kg Epi 1 1000 ** 0.11 mg  IM\n- **Yellow 12kg Epi 1 1000 ** 0.12 mg  IM\n- **Yellow 13kg Epi 1 1000 ** 0.13 mg  IM\n- **Yellow 14kg Epi 1 1000 ** 0.14 mg  IM\n- **White 15kg Epi 1 1000 ** 0.15 mg  IM\n- **White 16kg Epi 1 1000 ** 0.16 mg  IM\n- **White 17kg Epi 1 1000 ** 0.17 mg  IM\n- **White 18kg Epi 1 1000 ** 0.18 mg  IM\n- **Blue 19kg Epi 1 1000 ** 0.19 mg  IM\n- **All Other Colors Epi 1 1000 ** 0.19 mg  IM\n\n**EPINEPHRINE CARDIAC ARREST - EXACT DOSING **\n- **Grey 3kg Epi Cardiac Arrest ** 0.01 mg/kg IV/IO  every 3-5 minutes\n- **Grey 4kg Epi Cardiac Arrest ** 0.01 mg/kg IV/IO  every 3-5 minutes\n- **Grey 5kg Epi Cardiac Arrest ** 0.01 mg/kg IV/IO  every 3-5 minutes\n- **Pink 6kg Epi Cardiac Arrest ** 0.01 mg/kg IV/IO  every 3-5 minutes\n- **Pink 7kg Epi Cardiac Arrest ** 0.01 mg/kg IV/IO  every 3-5 minutes\n- **Red 8kg Epi Cardiac Arrest ** 0.01 mg/kg IV/IO  every 3-5 minutes\n- **Red 9kg Epi Cardiac Arrest ** 0.01 mg/kg IV/IO  every 3-5 minutes\n- **Purple 10kg Epi Cardiac Arrest ** 0.01 mg/kg IV/IO  every 3-5 minutes\n- **Purple 11kg Epi Cardiac Arrest ** 0.01 mg/kg IV/IO  every 3-5 minutes\n- **Yellow 12kg Epi Cardiac Arrest ** 0.01 mg/kg IV/IO  every 3-5 minutes\n- **Yellow 13kg Epi Cardiac Arrest ** 0.01 mg/kg IV/IO  every 3-5 minutes\n- **Yellow 14kg Epi Cardiac Arrest ** 0.01 mg/kg IV/IO  every 3-5 minutes\n- **White 15kg Epi Cardiac Arrest ** 0.01 mg/kg IV/IO  every 3-5 minutes\n- **White 16kg Epi Cardiac Arrest ** 0.01 mg/kg IV/IO  every 3-5 minutes\n- **White 17kg Epi Cardiac Arrest ** 0.01 mg/kg IV/IO  every 3-5 minutes\n- **White 18kg Epi Cardiac Arrest ** 0.01 mg/kg IV/IO  every 3-5 minutes\n- **Blue 19kg Epi Cardiac Arrest ** 0.01 mg/kg IV/IO  every 3-5 minutes\n- **All Other Colors Epi Cardiac Arrest ** 0.01 mg/kg IV/IO every 3-5 minutes\n\n**ORANGE 24KG COMPREHENSIVE DATA - EXACT VALUES **\n- **Weight ** 24 kg\n- **Length ** 119-129 cm\n- **Age ** 7-9 years\n- **Color Code ** Orange\n\n**NORMAL VITAL SIGNS **\n- **Heart Rate ** 70-110 bpm\n- **Respirations ** 15-30 bpm\n- **Systolic BP ** >80 mmHg\n\n**CARDIOVERSION/DEFIBRILLATION SETTINGS **\n- **24kg Orange Cardioversion ** 24 joules , 48 joules \n- **24kg Orange Defibrillation ** 48 joules , 96 joules \n\n**AIRWAY MANAGEMENT **\n- **Supraglottic Airway ** igel Size 2.5\n- **Gastric Suction Catheter ** 12 F\n\n**COMPREHENSIVE MEDICATION DOSING - ORANGE 24KG **\n- **Adenosine ** 2.4 mg  rapid IV push\n- **Albuterol NEB ** 5 mg \n- **Amiodarone ** 120 mg \n- **Atropine ** 0.48 mg \n- **Calcium Chloride ** 480 mg  - Dilute 1 1 with NS\n- **Dextrose 10% slow IV ** 120 mL \n- **Diphenhydramine IV/IM ** 24 mg \n- **DuoDote™ ** 2 doses\n- **Epinephrine Push Dose ** 10 mcg \n- **Epinephrine 0.1mg/mL IV ** 0.24 mg \n- **Epinephrine 1mg/mL IM ** 0.24 mg \n- **Epinephrine 1mg/mL NEB ** 5 mg \n- **Fentanyl IV/IM ** 24 mcg \n- **Fentanyl IN ** 36 mcg \n- **Glucagon IM ** 1 mg \n- **Glucopaste ** 15 gm \n- **Hydroxocobalamin IV/IO ** 1680 mg  - Reconstitute 5g vial in 200ml NS\n- **Ketorolac slow IV/IO ** 12 mg \n- **Ketorolac IM ** 12 mg \n- **Lidocaine 2% IO ** 12 mg \n- **Midazolam Agitation/Sedation IV/IO ** 2.4 mg \n- **Midazolam Agitation/Sedation IN/IM ** 4.8 mg \n- **Midazolam Seizure ≥12mo IN/IM ** PediDOSE\n- **Morphine IV/IM/IO ** 2.4 mg \n- **Naloxone IV/IM/IN ** 2 mg \n- **Normal Saline IV Bolus ** 480 mL \n- **Ondansetron ODT ** 4 mg \n- **Sodium Bicarbonate ** 24 mEq  - Dilute 1 1 with NS\n\n**ORANGE 26KG COMPREHENSIVE DATA - EXACT VALUES **\n- **Weight ** 26 kg\n- **Length ** 119-129 cm\n- **Age ** 7-9 years\n- **Color Code ** Orange\n\n**NORMAL VITAL SIGNS **\n- **Heart Rate ** 70-110 bpm\n- **Respirations ** 15-30 bpm\n- **Systolic BP ** >80 mmHg\n\n**CARDIOVERSION/DEFIBRILLATION SETTINGS **\n- **26kg Orange Cardioversion ** 26 joules , 52 joules \n- **26kg Orange Defibrillation ** 52 joules , 104 joules \n\n**AIRWAY MANAGEMENT **\n- **Supraglottic Airway ** igel Size 2.5\n- **Gastric Suction Catheter ** 12 F\n\n**COMPREHENSIVE MEDICATION DOSING - ORANGE 26KG **\n- **Adenosine ** 2.6 mg  rapid IV push\n- **Albuterol NEB ** 5 mg \n- **Amiodarone ** 130 mg \n- **Atropine ** 0.5 mg \n- **Calcium Chloride ** 520 mg  - Dilute 1 1 with NS\n- **Dextrose 10% slow IV ** 125 mL \n- **Diphenhydramine IV/IM ** 26 mg \n- **DuoDote™ ** 2 doses\n- **Epinephrine Push Dose ** 10 mcg \n- **Epinephrine 0.1mg/mL IV ** 0.26 mg \n- **Epinephrine 1mg/mL IM ** 0.26 mg \n- **Epinephrine 1mg/mL NEB ** 5 mg \n- **Fentanyl IV/IM ** 26 mcg \n- **Fentanyl IN ** 39 mcg \n- **Glucagon IM ** 1 mg \n- **Glucopaste ** 15 gm \n- **Hydroxocobalamin IV/IO ** 1820 mg  - Reconstitute 5g vial in 200ml NS\n- **Ketorolac slow IV/IO ** 13 mg \n- **Ketorolac IM ** 13 mg \n- **Lidocaine 2% IO ** 13 mg \n- **Midazolam Agitation/Sedation IV/IO ** 2.6 mg \n- **Midazolam Agitation/Sedation IN/IM ** 5 mg \n- **Midazolam Seizure ≥12mo IN/IM ** PediDOSE\n- **Morphine IV/IM/IO ** 2.6 mg \n- **Naloxone IV/IM/IN ** 2 mg \n- **Normal Saline IV Bolus ** 520 mL \n- **Ondansetron ODT ** 4 mg \n- **Sodium Bicarbonate ** 26 mEq  - Dilute 1 1 with NS\n\n**ORANGE 28KG COMPREHENSIVE DATA - EXACT VALUES **\n- **Weight ** 28 kg\n- **Length ** 119-129 cm\n- **Age ** 7-9 years\n- **Color Code ** Orange\n\n**NORMAL VITAL SIGNS **\n- **Heart Rate ** 70-110 bpm\n- **Respirations ** 15-30 bpm\n- **Systolic BP ** >80 mmHg\n\n**CARDIOVERSION/DEFIBRILLATION SETTINGS **\n- **28kg Orange Cardioversion ** 28 joules , 56 joules \n- **28kg Orange Defibrillation ** 56 joules , 112 joules \n\n**AIRWAY MANAGEMENT **\n- **Supraglottic Airway ** igel Size 2.5\n- **Gastric Suction Catheter ** 12 F\n\n**COMPREHENSIVE MEDICATION DOSING - ORANGE 28KG **\n- **Adenosine ** 2.8 mg  rapid IV push\n- **Albuterol NEB ** 5 mg \n- **Amiodarone ** 140 mg \n- **Atropine ** 0.5 mg \n- **Calcium Chloride ** 560 mg  - Dilute 1 1 with NS\n- **Dextrose 10% slow IV ** 125-140 mL \n- **Diphenhydramine IV/IM ** 28 mg \n- **DuoDote™ ** 2 doses\n- **Epinephrine Push Dose ** 10 mcg \n- **Epinephrine 0.1mg/mL IV ** 0.28 mg \n- **Epinephrine 1mg/mL IM ** 0.28 mg \n- **Epinephrine 1mg/mL NEB ** 5 mg \n- **Fentanyl IV/IM ** 28 mcg \n- **Fentanyl IN ** 42 mcg \n- **Glucagon IM ** 1 mg \n- **Glucopaste ** 15 gm \n- **Hydroxocobalamin IV/IO ** 1960 mg  - Reconstitute 5g vial in 200ml NS\n- **Ketorolac slow IV/IO ** 14 mg \n- **Ketorolac IM ** 14 mg \n- **Lidocaine 2% IO ** 14 mg \n- **Midazolam Agitation/Sedation IV/IO ** 2.8 mg \n- **Midazolam Agitation/Sedation IN/IM ** 5 mg \n- **Midazolam Seizure ≥12mo IN/IM ** PediDOSE\n- **Morphine IV/IM/IO ** 2.8 mg \n- **Naloxone IV/IM/IN ** 2 mg \n- **Normal Saline IV Bolus ** 560 mL \n- **Ondansetron ODT ** 4 mg \n- **Sodium Bicarbonate ** 28 mEq  - Dilute 1 1 with NS\n\n**GREEN 30KG COMPREHENSIVE DATA - EXACT VALUES **\n- **Weight ** 30 kg\n- **Length ** 129-141.5 cm\n- **Age ** 10-12 years\n- **Color Code ** Green\n\n**NORMAL VITAL SIGNS **\n- **Heart Rate ** 60-100 bpm\n- **Respirations ** 15-20 bpm\n- **Systolic BP ** >90 mmHg\n\n**CARDIOVERSION/DEFIBRILLATION SETTINGS **\n- **30kg Green Cardioversion ** 30 joules , 60 joules \n- **30kg Green Defibrillation ** 60 joules , 120 joules \n\n**AIRWAY MANAGEMENT **\n- **Supraglottic Airway ** igel Size 2.5\n- **Gastric Suction Catheter ** 12 F\n\n**COMPREHENSIVE MEDICATION DOSING - GREEN 30KG **\n- **Adenosine ** 3 mg  rapid IV push\n- **Albuterol NEB ** 5 mg \n- **Amiodarone ** 150 mg \n- **Atropine ** 0.5 mg \n- **Calcium Chloride ** 600 mg  - Dilute 1 1 with NS\n- **Dextrose 10% slow IV ** 125-150 mL \n- **Diphenhydramine IV/IM ** 30 mg \n- **DuoDote™ ** 2 doses\n- **Epinephrine Push Dose ** 10 mcg \n- **Epinephrine 0.1mg/mL IV ** 0.3 mg \n- **Epinephrine 1mg/mL IM ** 0.3 mg \n- **Epinephrine 1mg/mL NEB ** 5 mg \n- **Fentanyl IV/IM ** 30 mcg \n- **Fentanyl IN ** 45 mcg \n- **Glucagon IM ** 1 mg \n- **Glucopaste ** 15 gm \n- **Hydroxocobalamin IV/IO ** 2100 mg  - Reconstitute 5g vial in 200ml NS\n- **Ketorolac slow IV/IO ** 15 mg \n- **Ketorolac IM ** 15 mg \n- **Lidocaine 2% IO ** 15 mg \n- **Midazolam Agitation/Sedation IV/IO ** 3 mg \n- **Midazolam Agitation/Sedation IN/IM ** 5 mg \n- **Midazolam Seizure ≥12mo IN/IM ** PediDOSE\n- **Morphine IV/IM/IO ** 3 mg \n- **Naloxone IV/IM/IN ** 2 mg \n- **Normal Saline IV Bolus ** 600 mL \n- **Ondansetron ODT ** 4 mg \n- **Sodium Bicarbonate ** 30 mEq  - Dilute 1 1 with NS\n\n**GREEN 32KG COMPREHENSIVE DATA - EXACT VALUES **\n- **Weight ** 32 kg\n- **Length ** 129-141.5 cm\n- **Age ** 10-12 years\n- **Color Code ** Green\n\n**NORMAL VITAL SIGNS **\n- **Heart Rate ** 60-100 bpm\n- **Respirations ** 15-20 bpm\n- **Systolic BP ** >90 mmHg\n\n**CARDIOVERSION/DEFIBRILLATION SETTINGS **\n- **32kg Green Cardioversion ** 32 joules , 64 joules \n- **32kg Green Defibrillation ** 64 joules , 128 joules \n\n**AIRWAY MANAGEMENT **\n- **Supraglottic Airway ** igel Size 2.5\n- **Gastric Suction Catheter ** 12 F\n\n**COMPREHENSIVE MEDICATION DOSING - GREEN 32KG **\n- **Adenosine ** 3.2 mg  rapid IV push\n- **Albuterol NEB ** 5 mg \n- **Amiodarone ** 160 mg \n- **Atropine ** 0.5 mg \n- **Calcium Chloride ** 640 mg  - Dilute 1 1 with NS\n- **Dextrose 10% slow IV ** 125-160 mL \n- **Diphenhydramine IV/IM ** 32 mg \n- **DuoDote™ ** 2 doses\n- **Epinephrine Push Dose ** 10 mcg \n- **Epinephrine 0.1mg/mL IV ** 0.32 mg \n- **Epinephrine 1mg/mL IM ** 0.32 mg \n- **Epinephrine 1mg/mL NEB ** 5 mg \n- **Fentanyl IV/IM ** 32 mcg \n- **Fentanyl IN ** 48 mcg \n- **Glucagon IM ** 1 mg \n- **Glucopaste ** 15 gm \n- **Hydroxocobalamin IV/IO ** 2240 mg  - Reconstitute 5g vial in 200ml NS\n- **Ketorolac slow IV/IO ** 15 mg \n- **Ketorolac IM ** 15 mg \n- **Lidocaine 2% IO ** 16 mg \n- **Midazolam Agitation/Sedation IV/IO ** 3.2 mg \n- **Midazolam Agitation/Sedation IN/IM ** 5 mg \n- **Midazolam Seizure ≥12mo IN/IM ** PediDOSE\n- **Morphine IV/IM/IO ** 3.2 mg \n- **Naloxone IV/IM/IN ** 2 mg \n- **Normal Saline IV Bolus ** 640 mL \n- **Ondansetron ODT ** 4 mg \n- **Sodium Bicarbonate ** 32 mEq  - Dilute 1 1 with NS\n\n**GREEN 34KG COMPREHENSIVE DATA - EXACT VALUES **\n- **Weight ** 34 kg\n- **Length ** 129-141.5 cm\n- **Age ** 10-12 years\n- **Color Code ** Green\n\n**NORMAL VITAL SIGNS **\n- **Heart Rate ** 60-100 bpm\n- **Respirations ** 15-20 bpm\n- **Systolic BP ** >90 mmHg\n\n**CARDIOVERSION/DEFIBRILLATION SETTINGS **\n- **34kg Green Cardioversion ** 34 joules , 68 joules \n- **34kg Green Defibrillation ** 68 joules , 136 joules \n\n**AIRWAY MANAGEMENT **\n- **Supraglottic Airway ** igel Size 2.5\n- **Gastric Suction Catheter ** 12 F\n\n**COMPREHENSIVE MEDICATION DOSING - GREEN 34KG **\n- **Adenosine ** 3.4 mg  rapid IV push\n- **Albuterol NEB ** 5 mg \n- **Amiodarone ** 170 mg \n- **Atropine ** 0.5 mg \n- **Calcium Chloride ** 680 mg  - Dilute 1 1 with NS\n- **Dextrose 10% slow IV ** 125-170 mL \n- **Diphenhydramine IV/IM ** 34 mg \n- **DuoDote™ ** 2 doses\n- **Epinephrine Push Dose ** 10 mcg \n- **Epinephrine 0.1mg/mL IV ** 0.34 mg \n- **Epinephrine 1mg/mL IM ** 0.34 mg \n- **Epinephrine 1mg/mL NEB ** 5 mg \n- **Fentanyl IV/IM ** 34 mcg \n- **Fentanyl IN ** 50 mcg \n- **Glucagon IM ** 1 mg \n- **Glucopaste ** 15 gm \n- **Hydroxocobalamin IV/IO ** 2380 mg  - Reconstitute 5g vial in 200ml NS\n- **Ketorolac slow IV/IO ** 15 mg \n- **Ketorolac IM ** 15 mg \n- **Lidocaine 2% IO ** 17 mg \n- **Midazolam Agitation/Sedation IV/IO ** 3.4 mg \n- **Midazolam Agitation/Sedation IN/IM ** 5 mg \n- **Midazolam Seizure ≥12mo IN/IM ** PediDOSE\n- **Morphine IV/IM/IO ** 3.4 mg \n- **Naloxone IV/IM/IN ** 2 mg \n- **Normal Saline IV Bolus ** 680 mL \n- **Ondansetron ODT ** 4 mg \n- **Sodium Bicarbonate ** 34 mEq  - Dilute 1 1 with NS\n\n**GREEN 36KG COMPREHENSIVE DATA - EXACT VALUES **\n- **Weight ** 36 kg\n- **Length ** 129-141.5 cm\n- **Age ** 10-12 years\n- **Color Code ** Green\n\n**NORMAL VITAL SIGNS **\n- **Heart Rate ** 60-100 bpm\n- **Respirations ** 15-20 bpm\n- **Systolic BP ** >90 mmHg\n\n**CARDIOVERSION/DEFIBRILLATION SETTINGS **\n- **36kg Green Cardioversion ** 36 joules , 72 joules \n- **36kg Green Defibrillation ** 72 joules , 144 joules \n\n**AIRWAY MANAGEMENT **\n- **Supraglottic Airway ** igel Size 2.5\n- **Gastric Suction Catheter ** 12 F\n\n**COMPREHENSIVE MEDICATION DOSING - GREEN 36KG **\n- **Adenosine ** 3.6 mg  rapid IV push\n- **Albuterol NEB ** 5 mg \n- **Amiodarone ** 180 mg \n- **Atropine ** 0.5 mg \n- **Calcium Chloride ** 720 mg  - Dilute 1 1 with NS\n- **Dextrose 10% slow IV ** 125-180 mL \n- **Diphenhydramine IV/IM ** 36 mg \n- **DuoDote™ ** 2 doses\n- **Epinephrine Push Dose ** 10 mcg \n- **Epinephrine 0.1mg/mL IV ** 0.36 mg \n- **Epinephrine 1mg/mL IM ** 0.36 mg \n- **Epinephrine 1mg/mL NEB ** 5 mg \n- **Fentanyl IV/IM ** 36 mcg \n- **Fentanyl IN ** 50 mcg \n- **Glucagon IM ** 1 mg \n- **Glucopaste ** 15 gm \n- **Hydroxocobalamin IV/IO ** 2520 mg  - Reconstitute 5g vial in 200ml NS\n- **Ketorolac slow IV/IO ** 15 mg \n- **Ketorolac IM ** 15 mg \n- **Lidocaine 2% IO ** 18 mg \n- **Midazolam Agitation/Sedation IV/IO ** 3.6 mg \n- **Midazolam Agitation/Sedation IN/IM ** 5 mg \n- **Midazolam Seizure ≥12mo IN/IM ** PediDOSE\n- **Morphine IV/IM/IO ** 3.6 mg \n- **Naloxone IV/IM/IN ** 2 mg \n- **Normal Saline IV Bolus ** 720 mL \n- **Ondansetron ODT ** 4 mg \n- **Sodium Bicarbonate ** 36 mEq  - Dilute 1 1 with NS\n\n**CRITICAL ** These are the EXACT values from the user's screenshots. Use these values for ALL pediatric color code dosing queries."
  },
  {
    "id": "ems-amiodarone-dosing",
    "title": "Amiodarone Dosing - Adult and Pediatric",
    "category": "Medication",
    "keywords": ["amiodarone", "dosing", "adult", "pediatric", "cardiac", "arrest", "dysrhythmia", "vt", "vf", "ventricular", "tachycardia", "fibrillation"],
    "content": "**AMIODARONE DOSING - LA COUNTY EMS**\n\n**ADULT DOSING **\n- **Cardiac Arrest ** 300mg  IV/IO\n- **May repeat ** 150mg  IV/IO x1 prn after additional defibrillation x2\n- **Maximum total dose ** 450mg\n\n**PEDIATRIC DOSING **\n- **Cardiac Arrest ** 5mg/kg  IV/IO dose per MCG 1309\n- **Maximum total dose ** 300mg\n\n**INDICATIONS **\n- Cardiac Arrest - Non-Traumatic   pulseless ventricular tachycardia or persistent/recurrent ventricular fibrillation \n\n**MECHANISM OF ACTION **\n- Class III antiarrhythmic agent\n- Inhibits adrenergic stimulation\n- Affects sodium, potassium, and calcium channels\n- Markedly prolongs action potential and delays repolarization\n- Decreases AV conduction and sinus node function\n\n**PHARMACOKINETICS **\n- Onset  minutes after IV bolus administration\n\n**CONTRAINDICATIONS **\n- None in cardiac arrest\n\n**ADVERSE EFFECTS **\n- Bradysrhythmias\n- Congestive heart failure\n- Hypotension"
  },
  {
    "id": "ems-epinephrine-comprehensive",
    "title": "Epinephrine Comprehensive Reference - LA County EMS",
    "category": "Medication",
    "keywords": ["epinephrine", "epi", "adult", "pediatric", "dosing", "indications", "anaphylaxis", "cardiac arrest", "dysrhythmia", "bradycardia", "respiratory distress", "bronchospasm", "airway obstruction", "shock", "hypotension", "push-dose", "nebulizer", "stridor", "croup", "tracheitis"],
    "content": "**EPINEPHRINE COMPREHENSIVE REFERENCE - LA COUNTY EMS**\n\n**CLASSIFICATION ** Sympathomimetic\n\n**LA COUNTY PREHOSPITAL INDICATIONS **\n- **Anaphylaxis**\n- **Cardiac Arrest - Non-Traumatic ** cardiac arrest resuscitation, hypotension after return of spontaneous circulation  not responsive to IV fluid resuscitation\n- **Cardiac Dysrhythmia ** symptomatic bradycardia not responsive to atropine and transcutaneous pacing for adults; and for symptomatic bradycardia unresponsive to oxygenation and ventilation for pediatric patients\n- **Respiratory Distress / Bronchospasm ** asthma, reactive bronchospasm \n- **Airway Obstruction ** stridor or visible airway swelling, croup/tracheitis in pediatrics\n- **Shock / Hypotension ** non-traumatic hypotension not responsive to IV fluid resuscitation\n\n**OTHER COMMON INDICATIONS  ** None\n\n**ADULT DOSE **\n- **Anaphylaxis ** 0.5mg  IM in the lateral thigh, may repeat every 10 min x2 prn, maximum total 3 doses\n- **Cardiac Arrest ** 1mg  10mL IV/IO may repeat every 5 min x2, maximum total dose 3mg\n- **Non-traumatic shock  ** Push-dose epinephrine - mix 9mL normal saline with 1mL epinephrine 0.1mg/mL  in a 10mL syringe. Administer push-dose epinephrine 1mL IV/IO every 1-5 min as needed to maintain SBP >90mmHg\n- **Respiratory Distress/Bronchospasm ** 0.5mg  IM in the lateral thigh\n- **Airway Obstruction - Stridor ** Epinephrine  administer 5mg  via neb, repeat x1 in 10 min prn\n- **Airway Obstruction - Airway swelling ** Epinephrine  administer 0.5mg  IM, repeat every 10 min x2 prn, maximum total 3 doses\n\n**PEDIATRIC DOSE  **\n- **Anaphylaxis ** 0.01mg/kg  IM in the lateral thigh, may repeat every 10 min x2 prn for persistent symptoms, maximum total 3 doses\n- **Cardiac Arrest ** 0.01mg/kg  IV/IO may repeat every 5 min, maximum single dose 1mg, and maximum 3 total doses\n- **Cardiac Dysrhythmia - Symptomatic bradycardia ** 0.01mg/kg  slow IV/IO push\n- **Shock / Hypotension  ** Push-dose epinephrine - mix 9mL normal saline with 1mL epinephrine  IV formulation in a 10mL syringe. Administer push-dose epinephrine  every 1-5 min as needed to maintain SBP >70mmHg\n- **Respiratory Distress/Bronchospasm ** Epinephrine  0.01mg/kg IM in the lateral thigh\n- **Airway obstruction - Stridor from croup/tracheitis **\n  - **<1 year old ** Epinephrine  2.5mL via neb\n  - **≥ 1 year of age ** Epinephrine  5mL via neb\n  - Repeat x1 in 10 min prn, maximum 2 total doses prior to Base contact\n- **General ** Epinephrine  0.01mg/kg IM dose per MCG 1309, repeat every 10 min prn x2, maximum 3 total doses prior to Base contact\n\n**CONTRAINDICATIONS **\n- None\n\n**MECHANISM OF ACTION **\n- Sympathomimetic agent\n- Stimulates alpha and beta adrenergic receptors\n- Increases heart rate, contractility, and blood pressure\n- Bronchodilator effects\n- Vasoconstrictor effects\n\n**PHARMACOKINETICS **\n- Onset  Immediate , 1-2 minutes \n- Duration  3-5 minutes , 10-20 minutes \n- Half-life  2-3 minutes\n\n**ADVERSE EFFECTS **\n- Tachycardia\n- Hypertension\n- Arrhythmias\n- Anxiety\n- Tremor\n- Headache\n- Nausea\n- Sweating\n\n**CRITICAL NOTES **\n- Always use correct concentration for intended route\n- Monitor vital signs closely\n- Have advanced airway equipment available\n- Document all doses and responses\n- Contact medical control for guidance when appropriate"
  },
  {
    "id": "ems-fentanyl-comprehensive",
    "title": "Fentanyl Comprehensive Reference - LA County EMS",
    "category": "Medication",
    "keywords": ["fentanyl", "opioid", "analgesic", "pain", "management", "adult", "pediatric", "dosing", "indications", "contraindications", "mechanism", "pharmacokinetics", "adverse", "effects", "interactions"],
    "content": "**FENTANYL COMPREHENSIVE REFERENCE - LA COUNTY EMS**\n\n**CLASSIFICATION ** Synthetic opioid\n\n**LA COUNTY PREHOSPITAL INDICATIONS **\n- Multiple provider impressions  pain management\n\n**OTHER COMMON INDICATIONS  ** None\n\n**ADULT DOSE **\n- **50mcg  slow IV/IO push or IM/IN**\n- **Repeat ** every 5 min prn\n- **Maximum total dose prior to Base contact ** 150mcg\n- **Contact Base for additional pain management after maximum dose administered ** may repeat dose for a maximum total dose of 250mcg\n\n**PEDIATRIC DOSE  **\n- **1mcg/kg  slow IV/IO push or IM**\n- **OR 1.5mcg/kg  IN**\n- **Repeat ** in 5 min prn x1\n- **Maximum 2 total doses prior to Base contact**\n- **Contact Base for additional pain management after maximum dose administered ** may repeat dose for a maximum 4 total doses\n\n**MECHANISM OF ACTION **\n- Narcotic agonist-analgesic of opiate receptors\n- Inhibits ascending pain pathways thus altering response to pain\n- Increases pain threshold\n- Produces analgesia, respiratory depression and sedation\n\n**PHARMACOKINETICS **\n- **Onset ** immediate\n- **Peak ** 3-5 min\n- **Duration ** 30-60 min\n\n**CONTRAINDICATIONS **\n- Hypersensitivity\n- Pregnant patients in labor\n\n**INTERACTIONS **\n- Alcohol and other central nervous system depressants potentiate its effect\n\n**ADVERSE EFFECTS **\n- **Chest wall stiffness / Chest wall pain**\n- **Delirium / Convulsions **\n- **Muscle stiffness**\n- **Nausea and vomiting **\n\n**CRITICAL NOTES **\n- Monitor respiratory status closely\n- Have naloxone readily available\n- Assess pain level before and after administration\n- Document all doses and patient response\n- Contact medical control for additional doses beyond maximum\n- Use appropriate route based on patient condition and access availability"
  },
  {
    "id": "ems-glucagon-comprehensive",
    "title": "Glucagon Comprehensive Reference - LA County EMS",
    "category": "Medication",
    "keywords": ["glucagon", "hormone", "pancreatic", "hypoglycemia", "glucose", "adult", "pediatric", "dosing", "indications", "contraindications", "mechanism", "pharmacokinetics", "adverse", "effects", "interactions", "insulinoma"],
    "content": "**GLUCAGON COMPREHENSIVE REFERENCE - LA COUNTY EMS**\n\n**CLASSIFICATION ** Hormone \n\n**LA COUNTY PREHOSPITAL INDICATIONS **\n- **Hypoglycemia ** glucose <60mg/dL and venous access cannot be established\n\n**OTHER COMMON INDICATIONS  **\n- Clearance of impacted esophageal foreign body  in ED/monitored settings\n- Treatment of beta-blocker overdose and/or adjunctive treatment of calcium channel blocker overdose\n\n**ADULT DOSE **\n- **1mg  IM**\n- **May repeat ** x1 in 20 min prn\n\n**PEDIATRIC DOSE **\n- **< 1 year of age ** 0.5mL  IM, may repeat x1 in 20 min prn\n- **≥ 1 year of age ** 1.0mL  IM, may repeat x1 in 20 min prn\n\n**MECHANISM OF ACTION **\n- A hormone naturally produced by pancreatic alpha cells of the islets of Langerhans\n- Causes breakdown of glycogen  to glucose\n- Inhibits the synthesis of glycogen from glucose\n- The combined actions increase the blood levels of glucose\n\n**PHARMACOKINETICS **\n- **Onset ** 5-20 min\n- **Duration ** 1-1.5 hr\n\n**CONTRAINDICATIONS **\n- In patients with known insulinoma , glucagon will produce worsening hypoglycemia\n\n**INTERACTIONS **\n- None\n\n**ADVERSE EFFECTS **\n- Hypotension\n- Nausea and vomiting\n\n**PREHOSPITAL CONSIDERATIONS **\n- Use mixture immediately after reconstitution of dry powder and provided solution\n- Patient usually awakens from hypoglycemic coma 5-20 min after glucagon injection\n- PO carbohydrates should be given as soon as possible after patient regains consciousness\n- Symptoms such as headache, nausea and weakness may persist after recovery from hypoglycemic reaction\n\n**CRITICAL NOTES **\n- Only use when venous access cannot be established\n- Check blood glucose before administration\n- Reconstitute immediately before use\n- Monitor patient response closely\n- Administer oral carbohydrates as soon as patient regains consciousness\n- Document blood glucose levels and patient response"
  },
  {
    "id": "ems-hydroxocobalamin-comprehensive",
    "title": "Hydroxocobalamin Comprehensive Reference - LA County EMS",
    "category": "Medication",
    "keywords": ["hydroxocobalamin", "b12", "cyanide", "toxicity", "antidote", "adult", "pediatric", "dosing", "indications", "contraindications", "mechanism", "pharmacokinetics", "adverse", "effects", "interactions", "sodium", "thiosulfate", "nitrite"],
    "content": "**HYDROXOCOBALAMIN COMPREHENSIVE REFERENCE - LA COUNTY EMS**\n\n**CLASSIFICATION ** Synthetic B12, anti-anemic\n\n**LA COUNTY PREHOSPITAL INDICATIONS **\n- **Cyanide toxicity ** cardiovascular, neurologic, and/or respiratory compromise due to suspected or known cyanide exposure\n\n**OTHER COMMON INDICATIONS  **\n- B12 deficiency\n\n**ADULT DOSE **\n- **5 grams  reconstituted in 200mL of Normal Saline IV/IO and infused over 15 minutes**\n- **May repeat ** x1 in 15 minutes\n\n**PEDIATRIC DOSE **\n- **70mg/kg  infused over 15 minutes**\n- **Reconstitute ** 5 grams in 200mL of Normal Saline and infuse weight-based dose\n- **May repeat ** x1 in 15 minutes\n\n**MECHANISM OF ACTION **\n- Contains cobalt compounds that bind to and detoxify cyanide\n- Thereby preventing its binding to cytochrome c oxidase which leads to inhibition of cellular respiration\n\n**PHARMACOKINETICS **\n- **Onset ** immediate\n- **Duration half-life ** 24 hours\n\n**CONTRAINDICATIONS **\n- Hypersensitivity\n\n**INTERACTIONS **\n- Sodium thiosulfate, sodium nitrite\n\n**ADVERSE EFFECTS **\n- Allergic reactions\n- Renal injury\n- Increase in blood pressure\n\n**PREHOSPITAL CONSIDERATIONS **\n- Do not co-administer with other medications through the same vascular access; flush in between\n- Avoid administration through the same IV/IO as blood products\n- After administration pulse oximetry and co-oximetry will be inaccurate and may overestimate\n\n**CRITICAL NOTES **\n- Use only for confirmed or suspected cyanide toxicity\n- Reconstitute immediately before administration\n- Infuse over exactly 15 minutes\n- Monitor for allergic reactions\n- Document time of administration and patient response\n- Consider repeat dose if patient condition does not improve\n- Be aware of pulse oximetry limitations after administration"
  },
  {
    "id": "ems-ketorolac-comprehensive",
    "title": "Ketorolac Comprehensive Reference - LA County EMS",
    "category": "Medication",
    "keywords": ["ketorolac", "nsaid", "anti-inflammatory", "analgesic", "pain", "management", "adult", "pediatric", "dosing", "indications", "contraindications", "mechanism", "pharmacokinetics", "adverse", "effects", "interactions", "cardiac", "chest", "pain"],
    "content": "**KETOROLAC COMPREHENSIVE REFERENCE - LA COUNTY EMS**\n\n**CLASSIFICATION ** Nonsteroidal Anti-inflammatory Drug \n\n**LA COUNTY PREHOSPITAL INDICATIONS **\n- Multiple provider impressions  pain management\n- **Avoid in cardiac chest pain**\n\n**OTHER COMMON INDICATIONS  ** None\n\n**ADULT DOSE **\n- **15mg  slow IV/IO push**\n- **OR 30mg  IM**\n\n**PEDIATRIC DOSE  **\n- **0.5mg/kg  slow IV/IO push/IM**\n- **Maximum dose ** 15mg by any route\n\n**MECHANISM OF ACTION **\n- Reversibly inhibits cyclooxygenase-1 and 2 enzymes, which decreases formation of prostaglandin precursors\n- Inhibits platelet function\n- Ketorolac has analgesic and anti-inflammatory properties\n\n**PHARMACOKINETICS **\n- **Onset ** minutes after IM/IV/IO administration\n\n**CONTRAINDICATIONS **\n- Active bleeding\n- Active wheezing\n- Age < 4 years old or > 65 years old\n- Allergy to NSAIDs\n- Current anticoagulation therapy\n- Current steroid use\n- Head or multisystem trauma\n- History of upper GI bleeding or peptic ulcer disease\n- History of renal disease or kidney transplant\n- Known or suspected pregnancy\n- Suspected sepsis or septic shock\n\n**INTERACTIONS **\n- May enhance the adverse/toxic effect of other NSAIDs\n- May enhance the antiplatelet effect of other agents with antiplatelet properties\n- It may be used if the patient is taking aspirin\n\n**ADVERSE EFFECTS **\n- Gastrointestinal bleeding\n- Renal dysfunction\n- Hypertension\n- Fluid retention\n- Headache\n- Dizziness\n- Nausea\n- Vomiting\n- Drowsiness\n\n**CRITICAL NOTES **\n- Avoid in cardiac chest pain\n- Use with caution in elderly patients\n- Monitor for signs of bleeding\n- Assess renal function before administration\n- Document pain level before and after administration\n- Consider alternative analgesics for high-risk patients\n- Maximum single dose  15mg by any route for pediatric patients"
  },
  {
    "id": "ems-lidocaine-comprehensive",
    "title": "Lidocaine Comprehensive Reference - LA County EMS",
    "category": "Medication",
    "keywords": ["lidocaine", "local", "anesthetic", "io", "intraosseous", "anesthesia", "adult", "pediatric", "dosing", "indications", "contraindications", "mechanism", "pharmacokinetics", "adverse", "effects", "interactions", "pain", "management"],
    "content": "**LIDOCAINE COMPREHENSIVE REFERENCE - LA COUNTY EMS**\n\n**CLASSIFICATION ** Local Anesthetic\n\n**LA COUNTY PREHOSPITAL INDICATIONS **\n- Multiple provider impressions  patients responsive to pain that have intraosseous  access\n\n**OTHER COMMON INDICATIONS  **\n- Topical, transmucosal or intradermal anesthesia\n- Ventricular arrhythmias refractory to other treatments\n\n**ADULT DOSE **\n- **2% 40mg slow IO push over 2 minutes**\n- **May give second dose ** 20 mg x1 prn\n\n**PEDIATRIC DOSE  **\n- **2% 0.5mg/kg  slow IO push over 2 minutes**\n- **Not to exceed adult dose**\n- **May repeat second dose ** at half the initial dose x1 prn\n\n**MECHANISM OF ACTION **\n- Inhibits sodium ion channels, stabilizing neuronal cell membranes\n- Causes a nerve conduction blockage\n\n**PHARMACOKINETICS **\n- **Onset ** 2 min\n- **Peak ** 3-5 min\n- **Duration ** 10-20 min\n\n**CONTRAINDICATIONS **\n- None, when used for anesthesia in IO placement\n\n**INTERACTIONS **\n- No significant interaction at therapeutic doses for IO placement\n- In larger doses, multiple interactions possible including potentiation of fentanyl and amiodarone\n\n**ADVERSE EFFECTS **\n- None for IO use\n- High doses have been associated with increased risk of seizure\n\n**PREHOSPITAL CONSIDERATIONS **\n- This should be given pre-infusion if IV fluids or infusion of other medications through the IO on patients that are responsive to pain\n- Lidocaine 2%  should be used\n- Slow infusion is necessary to ensure the lidocaine remains in the medullary space\n- A base order is not needed to administer lidocaine as part of the IO procedure\n\n**CRITICAL NOTES **\n- Use only for IO anesthesia in responsive patients\n- Must be preservative and epinephrine free\n- Administer slowly over 2 minutes\n- Monitor for signs of systemic toxicity\n- Document IO placement and lidocaine administration\n- Consider second dose if needed for pain management\n- Be aware of potential interactions with other medications"
  },
  {
    "id": "ems-midazolam-comprehensive",
    "title": "Midazolam Comprehensive Reference - LA County EMS",
    "category": "Medication",
    "keywords": ["midazolam", "sedative", "benzodiazepine", "seizure", "agitation", "behavioral", "psychiatric", "cardiac", "dysrhythmia", "adult", "pediatric", "dosing", "indications", "contraindications", "mechanism", "pharmacokinetics", "adverse", "effects", "interactions", "gaba", "anxiolytic", "anticonvulsant"],
    "content": "**MIDAZOLAM COMPREHENSIVE REFERENCE - LA COUNTY EMS**\n\n**CLASSIFICATION ** Sedative, benzodiazepine\n\n**LA COUNTY PREHOSPITAL INDICATIONS **\n- **Behavioral / Psychiatric Crisis / Severe Agitation ** patients requiring restraints for patient and provider safety\n- **Cardiac Dysrhythmia ** sedation prior to and/or during synchronized cardioversion or transcutaneous pacing\n- **Sedation and amnestic agent ** for patients receiving manual/mechanical ventilation if already intubated\n- **Seizure - Active**\n\n**OTHER COMMON INDICATIONS  ** None\n\n**ADULT DOSE **\n- **Behavioral / Psychiatric Crisis ** 5mg  IM/IN/IV, repeat x1 in 5 min prn, maximum total dose prior to Base contact 10mg\n- **Cardiac Dysrhythmia - sedation prior to synchronized cardioversion / transcutaneous pacing ** 5mg  slow IV/IO push/IM/IN, may repeat x1 in 5 min prn, maximum total dose prior to Base contact 10mg\n- **Seizure - Active ** 10mg  IM/IN, contact Base for additional dosing, or 5mg  IV/IO, repeat x1 in 2 min prn if existing vascular access, maximum total dose prior to Base contact 10 mg\n- **Severe agitation with ALOC ** 5mg  IM/IN/IV, repeat x1 in 5 min prn, or 10mg  IM/IN single dose considering size of patient and level of risk, maximum total dose prior to Base Contact 10mg\n- **For all indications, with Base Contact may repeat as above up to a maximum total dose of 20mg**\n\n**PEDIATRIC DOSE  **\n- **Behavioral / Psychiatric Crisis / Severe Agitation ** 0.1mg/kg  IV or 0.2mg/kg  IM/IN, repeat x1 in 5 min, maximum single dose 5mg, maximum total dose prior to Base contact 10mg \n- **Cardiac Dysrhythmia - sedation prior to synchronized cardioversion / transcutaneous pacing ** 0.1mg/kg  IV/IO or 0.2mg/kg  IM/IN, repeat dosing every 5 min prn per Base order, maximum single dose 5mg\n- **Seizure - Active **\n  - **0-11 months  ** 0.2mg/kg  IM/IN, repeat x1 in 2 min prn, up to 2 doses prior to Base contact\n  - **12-16 months  ** 1.25 mg or 0.25mL IM/IN repeat x1 in 2 min prn, up to 2 doses prior to Base contact\n  - **17 months - 5 years  ** 2.5 mg or 0.5mL IM/IN repeat x1 in 2 min prn, up to 2 doses prior to Base contact\n  - **6-11 Years  ** 5mg or 1mL IM/IN repeat x1 in 2 min prn, up to 2 doses prior to Base contact\n  - **≥12 years  ** 10 mg or 2mL IM/IN repeat x1 in 2 min prn, Single dose prior to Base contact\n- **For patients with severe growth restriction , administer weight-based dose per color code**\n- **May repeat Midazolam as above, maximum total of 3 doses or 20 milligrams, whichever is less**\n\n**MECHANISM OF ACTION **\n- Binds to receptors at several sites within the CNS\n- Potentiates GABA receptor system which produces anxiolytic, anticonvulsant, muscle relaxant, and amnesic effects\n\n**PHARMACOKINETICS **\n- **Onset ** 3-5 min IV, 15-20 min IM, 6-14 min IN\n- **Duration ** 1-6 hours IV/IM\n\n**CONTRAINDICATIONS **\n- Respiratory depression\n- Shock / Poor perfusion \n\n**INTERACTIONS **\n- Risk of respiratory or central nervous system depression increases when used with diphenhydramine, fentanyl, morphine, or other opiate or sedative medications\n\n**ADVERSE EFFECTS **\n- Hypotension\n- Respiratory depression / arrest\n\n**PREHOSPITAL CONSIDERATIONS **\n- Closely monitor respiratory and cardiac function after administration\n- Caution in patients with suspected intoxication as midazolam can increase the risk for respiratory depression\n- For patients with severe agitation and violent behavior, IM/IN administration is recommended over IV for the initial dose for the safety of EMS personnel\n- If available, waveform EtCO2 monitoring should be instituted after administration\n- For patients who are poorly perfusing and require sedation for safety  or require a painful procedure , one should use judgment in consultation with Base\n\n**CRITICAL NOTES **\n- Monitor respiratory status closely\n- Use appropriate route based on patient condition and safety considerations\n- Document all doses and patient response\n- Contact Base for additional dosing beyond maximum\n- Consider patient's age and weight for pediatric dosing\n- Be aware of potential interactions with other sedatives\n- Use waveform EtCO2 monitoring when available"
  },
  {
    "id": "ems-morphine-comprehensive",
    "title": "Morphine Comprehensive Reference - LA County EMS",
    "category": "Medication",
    "keywords": ["morphine", "opiate", "analgesic", "pain", "management", "adult", "pediatric", "dosing", "indications", "contraindications", "mechanism", "pharmacokinetics", "adverse", "effects", "interactions", "narcotic", "agonist"],
    "content": "**MORPHINE COMPREHENSIVE REFERENCE - LA COUNTY EMS**\n\n**CLASSIFICATION ** Opiate Analgesic\n\n**LA COUNTY PREHOSPITAL INDICATIONS **\n- Multiple provider impressions  pain management\n\n**OTHER COMMON INDICATIONS  ** None\n\n**ADULT DOSE **\n- **4mg  slow IV/IO push or IM**\n- **Repeat ** every 5 min prn\n- **Maximum total dose prior to Base contact ** 12mg\n- **Contact Base for additional pain management after maximum dose administered ** may repeat dose for a maximum total dose of 20mg\n\n**PEDIATRIC DOSE  **\n- **0.1mg/kg  slow IV/IO push or IM**\n- **Repeat ** in 5 min x1\n- **Maximum 2 total doses prior to Base contact**\n- **Contact Base for additional pain management after maximum dose administered ** may repeat dose for a maximum 4 total doses\n\n**MECHANISM OF ACTION **\n- Narcotic agonist-analgesic of opiate receptors\n- Inhibits ascending pain pathways, thus altering response to pain\n\n**PHARMACOKINETICS **\n- **Onset ** immediate IV, 15-30 min IM\n- **Duration ** 2-7 hr\n\n**CONTRAINDICATIONS **\n- Hypotension or evidence or poor perfusion\n- History of allergy to morphine or other narcotic medications\n- Pregnant patients in labor\n\n**INTERACTIONS **\n- Central nervous system depressants, sedatives, barbiturates, alcohol, benzodiazepines and tricyclic depressants may potentiate the central nervous system and respiratory depressant effects\n\n**ADVERSE EFFECTS **\n- Decrease cough reflex\n- Disorientation\n- Hypotension\n- Nausea and vomiting\n- Respiratory depression\n\n**CRITICAL NOTES **\n- Monitor respiratory status closely\n- Have naloxone readily available\n- Assess pain level before and after administration\n- Document all doses and patient response\n- Contact medical control for additional doses beyond maximum\n- Use appropriate route based on patient condition and access availability\n- Monitor for signs of respiratory depression\n- Consider patient's hemodynamic status before administration"
  },
  {
    "id": "ems-naloxone-comprehensive",
    "title": "Naloxone Comprehensive Reference - LA County EMS",
    "category": "Medication",
    "keywords": ["naloxone", "opiate", "antagonist", "overdose", "poisoning", "ingestion", "adult", "pediatric", "dosing", "indications", "contraindications", "mechanism", "pharmacokinetics", "adverse", "effects", "interactions", "narcotic", "reversal"],
    "content": "**NALOXONE COMPREHENSIVE REFERENCE - LA COUNTY EMS**\n\n**CLASSIFICATION ** Opiate Antagonist\n\n**LA COUNTY PREHOSPITAL INDICATIONS **\n- **Overdose / Poisoning/ Ingestion ** suspected opiate overdose with altered mental status and hypoventilation/apnea\n\n**OTHER COMMON INDICATIONS  ** None\n\n**ADULT DOSE **\n- **2-4 mg IN **\n- **OR 2mg IM**\n- **OR 0.8-2mg IV push**\n- **Maximum dose all routes ** 8mg\n- **Titrate to adequate respiratory rate and tidal volume**\n\n**PEDIATRIC DOSE  **\n- **0.1mg/kg  IM/IN/IV**\n- **OR 2-4 mg IN if using pre-packaged nasal spray **\n- **Excludes newborns**\n- **Maximum dose all routes ** 8mg\n- **Titrate to adequate respiratory rate and tidal volume**\n\n**MECHANISM OF ACTION **\n- Competes for and displaces narcotic molecules from opiate receptors in the brain\n- Reverses the respiratory depression associated with overdose of narcotic agents\n\n**PHARMACOKINETICS **\n- **Onset ** < 2 min IV, 2-10min IM\n- **Duration ** 20-120 min\n\n**CONTRAINDICATIONS **\n- Hypersensitivity\n\n**INTERACTIONS **\n- None\n\n**ADVERSE EFFECTS **\n- Nausea and vomiting\n- Sweating\n- Tachycardia\n- Agitation\n- Hypertension\n- Abdominal pain\n- Acute pulmonary edema\n\n**CRITICAL NOTES **\n- Monitor respiratory status closely\n- Titrate to adequate respiratory rate and tidal volume\n- Be prepared for patient to become agitated or violent\n- Monitor for signs of acute pulmonary edema\n- Document all doses and patient response\n- Consider repeat dosing if patient becomes unresponsive again\n- Use appropriate route based on patient condition and access availability\n- Be aware that duration may be shorter than the opioid causing the overdose"
  },
  {
    "id": "ems-nitroglycerin-comprehensive",
    "title": "Nitroglycerin Comprehensive Reference - LA County EMS",
    "category": "Medication",
    "keywords": ["nitroglycerin", "nitrate", "vasodilator", "chest", "pain", "cardiac", "stemi", "pulmonary", "edema", "chf", "adult", "pediatric", "dosing", "indications", "contraindications", "mechanism", "pharmacokinetics", "adverse", "effects", "interactions", "sildenafil", "tadalafil", "vardenafil"],
    "content": "**NITROGLYCERIN COMPREHENSIVE REFERENCE - LA COUNTY EMS**\n\n**CLASSIFICATION ** Nitrate Vasodilator\n\n**LA COUNTY PREHOSPITAL INDICATIONS **\n- **Chest Pain - Suspected Cardiac**\n- **Chest Pain - STEMI**\n- **Pulmonary Edema / CHF**\n\n**OTHER COMMON INDICATIONS  **\n- Rapid blood pressure lowering in hypertensive emergency\n\n**ADULT DOSE **\n- **Chest Pain - Suspected Cardiac / Chest Pain - STEMI **\n  - **0.4 mg SL prn**\n  - **Repeat ** every 5 min prn x2, total 3 doses\n  - **Hold if ** SBP < 100mmHg or if the patient has taken sexually enhancing medication within 48 hours\n- **Pulmonary Edema / CHF **\n  - **0.4mg SL, for SBP ≥ 100mmHg**\n  - **0.8mg SL, for SBP ≥ 150mmHg**\n  - **1.2mg SL, for SBP ≥ 200mmHg**\n  - **Repeat ** every 3-5 min prn x2 for persistent dyspnea\n  - **Assess blood pressure prior to each administration and determine subsequent dose based on SBP as listed above**\n  - **Hold if ** SBP < 100mmHg\n\n**PEDIATRIC DOSE **\n- **Not recommended for pediatric administration**\n\n**MECHANISM OF ACTION **\n- Organic nitrate causing systemic venous dilatation, decreasing preload\n- Converted to nitric oxide, leading to vasodilation, relaxing smooth muscle, reducing preload and afterload, and myocardial oxygen demand\n- Improves coronary collateral circulation\n- Lowers BP, increases heart rate\n- Can cause occasional paradoxical bradycardia\n\n**PHARMACOKINETICS **\n- **Onset ** 1-3 min SL or TM\n- **Duration ** 20-30 min\n\n**CONTRAINDICATIONS **\n- Use of sexually enhancing/erectile dysfunction medications such as sildenafil, tadalafil or vardenafil within the past 48 hours\n- Hypotension with SBP < 100mmHg\n- Suspected cardiac tamponade\n\n**INTERACTIONS **\n- Alcohol, opiates, and antihypertensive agents may compound hypotensive effects\n\n**ADVERSE EFFECTS **\n- Hypotension\n- Headache\n- Dizziness\n- Flushing\n- Nausea\n- Vomiting\n- Syncope\n- Paradoxical bradycardia\n\n**CRITICAL NOTES **\n- Monitor blood pressure before each administration\n- Hold if SBP < 100mmHg\n- Check for recent use of erectile dysfunction medications\n- Document blood pressure and patient response\n- Use appropriate dose based on blood pressure for CHF\n- Monitor for signs of hypotension\n- Consider patient's hemodynamic status before administration\n- Be aware of potential drug interactions"
  },
  {
    "id": "ems-olanzapine-comprehensive",
    "title": "Olanzapine Comprehensive Reference - LA County EMS",
    "category": "Medication",
    "keywords": ["olanzapine", "atypical", "antipsychotic", "agitation", "cooperative", "patient", "self-administer", "adult", "pediatric", "dosing", "indications", "contraindications", "mechanism", "pharmacokinetics", "adverse", "effects", "interactions", "odt", "dementia", "psychosis", "ondansetron", "qt", "prolongation"],
    "content": "**OLANZAPINE COMPREHENSIVE REFERENCE - LA COUNTY EMS**\n\n**CLASSIFICATION ** Atypical anti-psychotic\n\n**LA COUNTY PREHOSPITAL INDICATIONS **\n- **Agitation in a cooperative patient **\n\n**OTHER COMMON INDICATIONS  ** None\n\n**ADULT DOSE **\n- **10 mg ODT given ONCE**\n\n**PEDIATRIC DOSE **\n- **10mg ODT given ONCE for pediatric patients longer than the length-based resuscitation tape**\n\n**MECHANISM OF ACTION **\n- 2nd generation anti-psychotic\n- Antagonizes serotonin 5-HT, dopamine, histamine and alpha-1 receptors\n- The precise mechanism is unknown but thought to be mediated through serotonin 5-HT and dopamine receptor sites\n\n**PHARMACOKINETICS **\n- **Onset ** 10-15 min\n- **Duration ** hours\n\n**CONTRAINDICATIONS **\n- Pregnancy\n- Dementia related psychosis\n- Patients ≤14 years AND on the length-based resuscitation tape\n- Ondansetron co-administration \n\n**INTERACTIONS **\n- CNS Depressant \n- Blood pressure lowering agents \n- QT prolonging drugs \n\n**ADVERSE EFFECTS **\n- Dry mouth\n- Dystonic reaction\n- Sedation\n- Dizziness\n- Orthostatic hypotension\n- Weight gain\n- Hyperglycemia\n- Extrapyramidal symptoms\n- Tardive dyskinesia\n- Neuroleptic malignant syndrome\n- QT prolongation\n\n**CRITICAL NOTES **\n- Patient must be cooperative and able to self-administer medication\n- Monitor for signs of dystonic reaction\n- Check for recent ondansetron administration\n- Monitor blood pressure for orthostatic hypotension\n- Document patient cooperation and ability to self-administer\n- Consider patient's age and length-based tape position for pediatric patients\n- Monitor for signs of neuroleptic malignant syndrome\n- Be aware of potential QT prolongation with other medications"
  },
  {
    "id": "ems-ondansetron-comprehensive",
    "title": "Ondansetron Comprehensive Reference - LA County EMS",
    "category": "Medication",
    "keywords": ["ondansetron", "antiemetic", "nausea", "vomiting", "fentanyl", "morphine", "adult", "pediatric", "dosing", "indications", "contraindications", "mechanism", "pharmacokinetics", "adverse", "effects", "interactions", "odt", "iv", "im", "serotonin", "5-ht3", "qt", "prolongation"],
    "content": "**ONDANSETRON COMPREHENSIVE REFERENCE - LA COUNTY EMS**\n\n**CLASSIFICATION ** Antiemetic\n\n**LA COUNTY PREHOSPITAL INDICATIONS **\n- **Multiple provider impressions ** Nausea and/or vomiting\n- **Prior to fentanyl or morphine administration** to reduce potential for nausea/vomiting\n\n**OTHER COMMON INDICATIONS  ** None\n\n**ADULT DOSE **\n- **4 mg ODT/IV/IM**\n- **May repeat x1 in 15 min prn**\n\n**PEDIATRIC DOSE **\n- **4 mg ODT, only for 4 years of age or older**\n\n**MECHANISM OF ACTION **\n- Has not been fully characterized but believed to function via serotonin antagonism at central and/or peripheral receptors\n- Serotonin receptors of the 5-HT3 type are present both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area of the medullary structure that controls vomiting\n\n**PHARMACOKINETICS **\n- **Onset ** 1-5 min\n- **Duration ** 4-6 hr\n\n**CONTRAINDICATIONS **\n- Known allergy to Ondansetron\n- Pregnancy, regardless of gestational age\n\n**INTERACTIONS **\n- Amiodarone and other QT prolonging drugs \n\n**ADVERSE EFFECTS **\n- Constipation\n- Headache\n- QT prolongation\n- Sedation\n\n**CRITICAL NOTES **\n- Check for known allergies before administration\n- Avoid in pregnant patients regardless of gestational age\n- Monitor for QT prolongation, especially with other QT-prolonging drugs\n- Consider giving before fentanyl or morphine to prevent nausea/vomiting\n- Document patient's age for pediatric administration \n- Monitor for signs of constipation\n- Be aware of potential drug interactions with amiodarone and other QT-prolonging medications"
  },
  {
    "id": "ems-pralidoxime-comprehensive",
    "title": "Pralidoxime Chloride  Comprehensive Reference - LA County EMS",
    "category": "Medication",
    "keywords": ["pralidoxime", "chloride", "duodote", "cholinesterase", "reactivator", "hazmat", "exposure", "nerve", "agent", "organophosphate", "poisoning", "atropine", "adult", "pediatric", "dosing", "indications", "contraindications", "mechanism", "pharmacokinetics", "adverse", "effects", "interactions", "im", "injection", "sevin", "carbamate", "inorganic", "phosphates"],
    "content": "**PRALIDOXIME CHLORIDE  COMPREHENSIVE REFERENCE - LA COUNTY EMS**\n\n**CLASSIFICATION ** Cholinesterase Reactivator\n\n**LA COUNTY PREHOSPITAL INDICATIONS **\n- **HAZMAT Exposure ** nerve agent or organophosphate poisoning\n\n**OTHER COMMON INDICATIONS  **\n- Antidote to toxicity from agents  used in treatment of myasthenia gravis\n\n**ADULT DOSE **\n- **Given in conjunction with atropine as a DuoDote injection - Atropine 2.1mg and Pralidoxime Chloride 600mg **\n- **Medications delivered sequentially by one syringe into 2 different areas of the muscle**\n- **Mild Exposure ** DuoDote™ IM x1\n- **Moderate Exposure ** DuoDote™ IM x2, one after another\n- **Severe Exposure ** DuoDote™ IM x3, one after another\n\n**PEDIATRIC DOSE **\n- **Pediatric patients longer than the length-based resuscitation tape  should receive adult dose**\n- **Pediatric patients between 3-36kg body weight, based on measurement using the length-based resuscitation tape , should be treated as follows **\n  - **Mild Exposure ** Atropine  0.02mg/kg IV/IM, dose as per MCG 1309\n  - **Moderate Exposure ** 1 DuoDote™ IM\n  - **Severe Exposure ** 1 or 2 DuoDote™ IM, one after the other when applicable, based on the table below \n\n**PEDIATRIC DOSING TABLE **\n- **Purple  ** 1 DuoDote™\n- **Orange  ** 2 DuoDotes™\n- **Other color codes ** Use individual atropine dosing per MCG 1309\n\n**MECHANISM OF ACTION **\n- Reactivates cholinesterase by displacing the enzyme from its receptor sites\n- The free enzyme then can resume its function of degrading accumulated acetylcholine, thereby restoring normal neuromuscular transmission\n- Pralidoxime also detoxifies some organophosphates by direct chemical reaction\n\n**PHARMACOKINETICS **\n- **Onset ** 2-3 min\n- **Peak effect ** 5-15 min\n- **Duration ** 2-3 hr\n\n**CONTRAINDICATIONS **\n- Poisonings with carbamate insecticide Sevin, inorganic phosphates, organophosphates with no anticholinesterase\n\n**INTERACTIONS **\n- None specifically mentioned\n\n**ADVERSE EFFECTS **\n- Injection site reactions\n- Nausea\n- Vomiting\n- Dizziness\n- Blurred vision\n- Headache\n- Muscle weakness\n- Tachycardia\n- Hypertension\n\n**CRITICAL NOTES **\n- Always administer with atropine as DuoDote™\n- Use different muscle sites for multiple injections\n- Administer sequentially, one after another\n- Monitor for signs of cholinergic crisis\n- Document exposure type \n- Use appropriate pediatric dosing based on Broselow™ tape\n- Monitor vital signs closely after administration\n- Be aware of specific contraindications for carbamate poisoning\n- Consider decontamination procedures\n- Document all doses and patient response"
  },
  {
    "id": "ems-sodium-bicarbonate-comprehensive",
    "title": "Sodium Bicarbonate Comprehensive Reference - LA County EMS",
    "category": "Medication",
    "keywords": ["sodium", "bicarbonate", "electrolyte", "alkalinizing", "agent", "cardiac", "arrest", "hyperkalemia", "tricyclic", "overdose", "crush", "injury", "syndrome", "adult", "pediatric", "dosing", "indications", "contraindications", "mechanism", "pharmacokinetics", "adverse", "effects", "interactions", "iv", "io", "push", "pulmonary", "edema", "hypernatremia", "hypocalcemia"],
    "content": "**SODIUM BICARBONATE COMPREHENSIVE REFERENCE - LA COUNTY EMS**\n\n**CLASSIFICATION ** Electrolyte / Alkalinizing Agent\n\n**LA COUNTY PREHOSPITAL INDICATIONS **\n- **Cardiac Arrest - Non-Traumatic ** suspected hyperkalemia, patients with renal failure\n- **Cardiac Dysrhythmia ** suspected hyperkalemia causing bradycardia\n- **Overdose / Poisoning / Ingestion ** suspected tricyclic overdose with ECG changes\n- **Traumatic Injury ** suspected hyperkalemia in the setting of crush injury or potential for development of crush syndrome \n\n**OTHER COMMON INDICATIONS  ** None\n\n**ADULT DOSE **\n- **50mEq  slow IV/IO push**\n- **For crush injury ** repeat x1 for persistent ECG abnormalities\n\n**PEDIATRIC DOSE **\n- **1mEq/kg  slow IV push, dose per MCG 1309**\n- **For crush injury ** repeat x1 for persistent ECG abnormalities\n\n**MECHANISM OF ACTION **\n- Increases blood and urinary pH by releasing a bicarbonate ion, which in turn neutralizes hydrogen ion concentration\n\n**PHARMACOKINETICS **\n- **Onset ** < 15 min \n- **Clinical effect ** < 15 min\n- **Duration ** 1-2 hr\n\n**CONTRAINDICATIONS **\n- Evidence of pulmonary edema\n- Hypernatremia or hypocalcemia\n\n**INTERACTIONS **\n- Precipitates to form calcium carbonate  when used with calcium chloride or calcium gluconate\n- Administer calcium chloride and sodium bicarbonate separately\n- Can reduce potency of epinephrine, flush line after administration\n\n**ADVERSE EFFECTS **\n- Extracellular alkalosis\n- Tissue damage if IV infiltrates\n- Pulmonary edema\n\n**PREHOSPITAL CONSIDERATIONS **\n- Multiple doses may be needed in TCA overdose when indicated\n\n**CRITICAL NOTES **\n- Administer slowly IV/IO push\n- Monitor for signs of pulmonary edema\n- Check for hypernatremia or hypocalcemia before administration\n- Do not mix with calcium chloride or calcium gluconate\n- Flush line after administration to prevent epinephrine inactivation\n- Consider multiple doses for tricyclic overdose\n- Administer prior to release of crushed tissue in crush injury\n- Monitor ECG for changes\n- Document indication and patient response\n- Use appropriate pediatric dosing per MCG 1309"
  },
  {
    "id": "ems-tranexamic-acid-comprehensive",
    "title": "Tranexamic Acid  Comprehensive Reference - LA County EMS",
    "category": "Medication",
    "keywords": ["tranexamic", "acid", "txa", "antifibrinolytic", "hemorrhage", "bleeding", "trauma", "postpartum", "adult", "pediatric", "dosing", "indications", "contraindications", "mechanism", "pharmacokinetics", "adverse", "effects", "interactions", "iv", "infusion", "normal", "saline", "pediatric", "age", "injury", "delivery", "brain", "injury", "cpr", "thrombotic", "dvt", "pe", "allergic"],
    "content": "**TRANEXAMIC ACID  COMPREHENSIVE REFERENCE - LA COUNTY EMS**\n\n**CLASSIFICATION ** Antifibrinolytic\n\n**LA COUNTY PREHOSPITAL INDICATIONS **\n- **Adult patients within 3 hours of traumatic injury with suspected internal truncal hemorrhage and systolic blood pressure  < 90mmHg or heart rate > SBP**\n- **Adult patients within 3 hours of traumatic injury with uncontrolled external/extremity hemorrhage despite applying pressure, and use of hemostatic agents and tourniquets where appropriate**\n- **Adult patients with post-partum hemorrhage as evidenced by ongoing bleeding and systolic blood pressure  < 90mmHg or heart rate > SBP or estimated blood loss > 500mL**\n\n**OTHER COMMON INDICATIONS  **\n- Confirmed traumatic brain injury with intracranial hemorrhage on CT scan\n- Uncontrolled epistaxis\n- Dental bleeding\n- Surgical bleeding\n- Heavy menstrual bleeding \n- Bleeding prophylaxis in patients with hemophilia \n\n**ADULT DOSE **\n- **1 gram in 50 or 100mL of Normal Saline infused over 10 minutes**\n\n**PEDIATRIC DOSE **\n- **Not applicable**\n\n**MECHANISM OF ACTION **\n- Antifibrinolytic agent that inhibits the activation of plasminogen to plasmin\n- Binds to plasminogen and prevents its conversion to plasmin, thereby preventing fibrinolysis\n- Stabilizes fibrin clots and reduces bleeding\n\n**PHARMACOKINETICS **\n- **Onset ** 5-15 min\n- **Duration ** 2-3 hours\n\n**CONTRAINDICATIONS **\n- Pediatric patients ≤14 years of age \n- Greater than 3 hours post injury/delivery\n- Isolated traumatic brain injury\n- Traumatic arrest with CPR >5 minutes\n- Active known thrombotic disease \n- Known allergic reaction to TXA\n\n**INTERACTIONS **\n- None for EMS\n\n**ADVERSE EFFECTS **\n- Nausea\n- Vomiting\n- Diarrhea\n- Headache\n- Dizziness\n- Hypotension\n- Thromboembolic events \n- Allergic reactions\n\n**CRITICAL NOTES **\n- **TIME-SENSITIVE ** Must be given within 3 hours of injury/delivery\n- **ADULT ONLY ** Not for pediatric patients ≤14 years\n- **NOT FOR ISOLATED TBI ** Do not use for isolated traumatic brain injury\n- **CPR LIMITATION ** Do not use if traumatic arrest with CPR >5 minutes\n- **THROMBOTIC RISK ** Avoid in patients with active thrombotic disease\n- **INFUSION RATE ** Must be infused over 10 minutes\n- **DILUTION ** Use 50 or 100mL of Normal Saline\n- **MONITORING ** Watch for signs of thrombosis\n- **DOCUMENTATION ** Document time of injury/delivery and administration\n- **CONTRAINDICATION CHECK ** Verify no active thrombotic disease\n- **ALLERGY CHECK ** Confirm no known TXA allergy"
  },
  {
    "id": "ems-policy-814-death-determination",
    "title": "LA County EMS Policy 814  Determination of Death in the Field - Complete Reference",
    "category": "Protocol",
    "keywords": ["policy", "814", "death", "determination", "pronouncement", "field", "criteria", "trauma", "cardiac", "arrest", "resuscitation", "asystole", "apnea", "pulseless", "decapitation", "crush", "injury", "decomposition", "incineration", "extrication", "penetrating", "blunt", "drowning", "rigor", "mortis", "lividity", "pupillary", "response", "pain", "stimuli", "dnr", "ahcd", "family", "consent", "ecpr", "rosc", "base", "physician", "consultation", "documentation", "coroner", "crime", "scene"],
    "content": "**LA COUNTY EMS POLICY 814  DETERMINATION OF DEATH IN THE FIELD - COMPLETE REFERENCE**\n\n**REFERENCE NO. 814**\n**SUBJECT  DETERMINATION / PRONOUNCEMENT OF DEATH IN THE FIELD**\n\n**SECTION I. POLICY - EMS PERSONNEL MAY DETERMINE DEATH IN THE FOLLOWING CIRCUMSTANCES **\n\n**A. In addition to the absence of respiration, cardiac activity, and neurologic reflexes, one or more of the following physical or circumstantial conditions exist **\n1. **Decapitation**\n2. **Massive crush injury**\n3. **Penetrating or blunt injury with evisceration of the heart, lung or brain**\n4. **Decomposition**\n5. **Incineration**\n6. **Pulseless, non-breathing victims with extrication time greater than fifteen minutes, where no resuscitative measures can be performed prior to extrication**\n7. **Penetrating trauma patients who, based on the paramedic's thorough assessment, are found apneic, pulseless, asystolic, and without pupillary reflexes upon the arrival of EMS personnel at the scene**\n8. **Blunt trauma patients found apneic, pulseless, and without organized ECG activity upon EMS arrival**\n9. **Pulseless, non-breathing victims in multiple victim incidents with insufficient medical resources**\n10. **Drowning victims where submersion has been greater than one hour**\n11. **Assessment of rigor mortis and post-mortem lividity**\n\n**B. ASSESSMENTS TO BE PERFORMED BY EMTs/PARAMEDICS TO CONFIRM ABSENCE OF RESPIRATORY, CARDIAC, AND NEUROLOGIC FUNCTION **\n\n**1. Assessment of respiratory status **\n- Ensure an open airway\n- Look, listen, and feel for respirations for a minimum of 30 seconds to confirm apnea\n\n**2. Assessment of cardiac status **\n- **Adults/Children ** Auscultate the apical pulse for 60 seconds to confirm the absence of heart sounds\n- **Adults/Children ** Palpate the carotid pulse for 60 seconds to confirm the absence of a pulse\n- **Infants ** Palpate the brachial pulse for a minimum of 60 seconds to confirm the absence of a pulse\n\n**3. Assessment of neurological reflexes **\n- **a.** Check for pupillary response with a penlight or flashlight to determine if pupils are fixed and dilated\n- **b.** Check and confirm unresponsive to pain stimuli\n\n**SECTION II. PATIENTS IN ATRAUMATIC CARDIOPULMONARY ARREST **\n\n**A. Patients who do not meet the conditions described in Section I.A. require immediate BLS measures to be initiated. If one or more of the following conditions is met, resuscitation may be discontinued and the patient is determined to be dead **\n\n1. **A valid standardized patient-designated directive indicating DNR**\n2. **A valid AHCD with written DNR instructions or the agent identified in the AHCD requesting no resuscitation**\n3. **Immediate family member present at scene **\n   - **a.** With a patient-designated directive on scene requesting no resuscitation\n   - **b.** Without said documents at scene, with full agreement of immediate family requesting no resuscitation, and EMS providers concur\n4. **Parent or legal guardian is required and must be present at scene to withhold or terminate resuscitation for patients less than 18 years of age**\n\n**B. Patients in atraumatic cardiopulmonary arrest who do not meet the conditions described in Section I require immediate cardiopulmonary resuscitation in accordance with Ref. No. 1210, Treatment Protocol  Cardiac Arrest. Base contact for medical direction shall be established when indicated by Ref. No. 1210.**\n\n**SECTION IIA. CRITERIA FOR EMS PERSONNEL TO DETERMINE DEATH **\n\n**EMS Personnel may determine death if a patient is in asystole after 20 minutes of quality cardiopulmonary resuscitation on scene and meets ALL of the following criteria **\n\n1. **Patient 18 years or greater**\n2. **Arrest not witnessed by EMS personnel**\n3. **No shockable rhythm identified at any time during the resuscitation**\n4. **No ROSC at any time during the resuscitation**\n5. **No hypothermia**\n\n**A. Base Physician consultation for pronouncement is not required if Section A is met.**\n**B. Base Physician contact shall be established to guide resuscitation and to make decisions regarding timing of transport, if transport is indicated, for patients in cardiopulmonary arrest who do not meet the conditions described in Section I or IIA of this policy. ECPR candidates are transported prior to Base Contact.**\n\n**SECTION III. PHYSICIAN GUIDELINES FOR TRANSPORT VERSUS TERMINATION **\n\n**A. Resuscitation should be continued on-scene until one of the following **\n1. **ROSC  is confirmed with a palpable pulse and rise in EtCO2. Paramedics should stabilize the patient for approximately 5 minutes per TP 1210 and then initiate transport.**\n2. **The patient is an ECPR  candidate but has not achieved ROSC despite initial on-scene resuscitation .**\n3. **The Base physician determines further resuscitative efforts are futile.**\n\n**B. Patients who have NOT maintained ROSC after on-scene resuscitation and stabilization should NOT be transported unless the Base physician determines transport is indicated and/or the patient meets ECPR criteria.**\n1. **Early transport for patients with ongoing resuscitation is NOT advised.**\n2. **The decision to transport a patient with refractory OHCA  should be based on the availability of therapies at the receiving center that are not available on scene.**\n\n**SECTION IV. CRIME SCENE RESPONSIBILITY, INCLUDING PRESUMED ACCIDENTAL DEATHS AND SUSPECTED SUICIDES **\n\n**A. Responsibility for medical management rests with the most medically qualified person on scene.**\n**B. Authority for crime scene management shall be vested in law enforcement.**\n\n**SECTION V. PROCEDURES FOLLOWING PRONOUNCEMENT OF DEATH **\n\n**A. The deceased should not be moved without the coroner's authorization, and any invasive equipment  should be left in place.**\n\n**NOTE  Exception for moving the deceased if the scene is unsafe, the body is a hazard, or at risk of loss . In such cases, EMS personnel may relocate the deceased to a safer location or transport to the most accessible receiving facility.**\n\n**B. If law enforcement or the coroner confirms it's not a coroner's case and a personal physician will sign the death certificate, invasive equipment used during resuscitation may be removed.**\n\n**C. EMS personnel to remain on scene until law enforcement arrives and, when appropriate, provide grief support to family members.**\n\n**SECTION VI. REQUIRED DOCUMENTATION FOR PATIENTS DETERMINED DEAD/PRONOUNCED IN THE FIELD **\n\n**A. Document the time and criteria used to determine death, the condition, location, and position of the body, and any care provided.**\n\n**B. Document the location and rationale if the deceased was moved, and if authorized by the coroner, the coroner's case number and representative.**\n\n**C. Document the time of pronouncement and the name of the pronouncing physician if base hospital contact was initiated.**\n\n**D. Document the name of the agent identified in the AHCD  or patient-designated directive, or the name of the immediate family member who made the decision to withhold or withdraw resuscitative measures, and obtaining their signature on the EMS Report Form.**\n\n**E. Procedures if the deceased is not a coroner's case and their personal physician is signing the death certificate.**\n\n**CRITICAL NOTES **\n- **TIME-SENSITIVE ** 20-minute rule for asystole after quality CPR\n- **AGE RESTRICTION ** Must be 18 years or greater for certain criteria\n- **WITNESS REQUIREMENT ** Arrest not witnessed by EMS personnel\n- **NO SHOCKABLE RHYTHM ** No shockable rhythm identified at any time\n- **NO ROSC ** No Return of Spontaneous Circulation at any time\n- **NO HYPOTHERMIA ** Must rule out hypothermia\n- **FAMILY CONSENT ** Parent/guardian required for patients <18 years\n- **DOCUMENTATION ** Comprehensive documentation required\n- **CORONER AUTHORIZATION ** Required before moving deceased\n- **LAW ENFORCEMENT ** Must remain on scene until arrival\n- **GRIEF SUPPORT ** Provide appropriate support to family members"
  },
  {
    "id": "ems-policy-832-minors-treatment",
    "title": "LA County EMS Policy 832  Treatment/Transport of Minors - Complete Reference",
    "category": "Protocol",
    "keywords": ["policy", "832", "minors", "treatment", "transport", "parental", "consent", "legal", "representative", "minor", "age", "married", "domestic", "partnership", "emergency", "medical", "condition", "armed", "forces", "self-sufficient", "emancipated", "pregnancy", "abortion", "sexual", "assault", "rape", "communicable", "disease", "sti", "alcohol", "substance", "abuse", "mental", "health", "restraint", "device", "fmvss", "213", "infants", "base", "contact", "law", "enforcement", "endangering", "health", "welfare", "refusing", "care", "transport"],
    "content": "**LA COUNTY EMS POLICY 832  TREATMENT/TRANSPORT OF MINORS - COMPLETE REFERENCE**\n\n**REFERENCE NO. 832**\n**SUBJECT  TREATMENT/TRANSPORT OF MINORS**\n\n**DEFINITIONS **\n- **Legal Representative ** A person who is granted custody or conservatorship of another person by a court of law\n- **Minor ** A person less than eighteen years of age\n\n**MINOR NOT REQUIRING PARENTAL CONSENT - A PERSON WHO IS **\n\n1. **Married or was previously married**\n2. **Currently or previously in a valid domestic partnership**\n3. **Not married and has an emergency medical condition and parent is not available**\n4. **On active duty with the Armed Forces**\n5. **Self-sufficient 14 years of age or older, living separate and apart from his/her parents, and managing his/her own financial affairs**\n6. **An emancipated minor with a declaration by the court or an identification card from the Department of Motor Vehicles**\n7. **Seeking care related to the treatment or prevention of pregnancy**\n8. **In need of care for sexual assault or rape**\n9. **Seeking care related to an abortion**\n10. **12 years of age or older and in need of care for communicable reportable disease, prevention of a sexually transmitted infection , alcohol or substance abuse, or outpatient mental health**\n\n**VOLUNTARY CONSENT **\n- Treatment or transport of a minor child shall be with the verbal or written consent of the parents or legal representative\n\n**PROCEDURES **\n\n**I. TREATMENT/TRANSPORT OF MINORS**\n\n**A. Emergency Medical Conditions **\n- In the absence of a parent or legal representative, minors with an emergency medical condition shall be treated and transported to the appropriate receiving facility or a specialty care center \n\n**B. Restraint Devices **\n- Minors should be transported using a restraint device appropriate for their size, weight, transport position, and medical condition\n- Restraint devices used should comply with the Federal Motor Vehicle Safety Standard  213\n\n**C. Parent Notification **\n- Hospital or provider agency personnel shall make every effort to inform a parent or legal representative where their child has been transported\n\n**D. Endangering Decisions **\n- If prehospital care personnel believe a parent or other legal representative of a minor is making a decision which appears to be endangering the health and welfare of the minor by refusing indicated immediate care or transport, law enforcement authorities should be involved\n\n**E. Infants ≤ 12 months of age **\n- Shall be transported, regardless of chief complaint and/or mechanism of injury, in accordance with Ref. No. 1200.2, Treatment Protocol  Base Contact Criteria\n\n**II. MINORS NOT REQUIRING TRANSPORT**\n\n**A. Release Criteria **\n- A minor child  months of age) who is evaluated by EMS personnel and determined not to be injured, to have sustained only minor injuries, or to have illnesses or injuries not requiring immediate treatment or transportation, may be released to \n  1. **Self** \n  2. **Parent or legal representative**\n  3. **A responsible adult at the scene**\n  4. **Designated care giver**\n  5. **Law enforcement**\n\n**B. Children 13-36 months of age **\n- Require base hospital contact and/or transport, except those with no medical complaint or with isolated minor extremity injury\n\n**C. Documentation **\n- Prehospital care personnel shall document on the EMS Report Form to whom the patient was released\n\n**CRITICAL NOTES **\n- **AGE REQUIREMENTS ** Different criteria for different age groups\n- **EMERGENCY CONDITIONS ** Always transport minors with emergency medical conditions\n- **PARENTAL CONSENT ** Required unless specific exceptions apply\n- **RESTRAINT DEVICES ** Must comply with FMVSS 213 standards\n- **INFANT TRANSPORT ** All infants ≤12 months must be transported\n- **BASE CONTACT ** Required for children 13-36 months except minor injuries\n- **LAW ENFORCEMENT ** Involve when parents endanger child's welfare\n- **DOCUMENTATION ** Document who patient was released to\n- **SELF-SUFFICIENT ** Must be 14+ years, living separately, managing finances\n- **EMANCIPATED ** Requires court declaration or DMV ID card\n- **MEDICAL CONDITIONS ** Emergency conditions override consent requirements\n- **SPECIALTY CENTERS ** Use appropriate receiving facilities \n- **COMMUNICABLE DISEASES ** 12+ years can consent for STI prevention, substance abuse, mental health\n- **SEXUAL ASSAULT ** Minors can consent for rape/assault care\n- **PREGNANCY CARE ** Minors can consent for pregnancy-related care including abortion"
  },
  {
    "id": "ems-policy-1232-stroke-cva-tia",
    "title": "LA County EMS Policy 1232  Stroke/CVA/TIA Treatment Protocol - Complete Reference",
    "category": "Protocol",
    "keywords": ["policy", "1232", "stroke", "cva", "tia", "cerebrovascular", "accident", "transient", "ischemic", "attack", "mlapss", "lams", "last", "known", "well", "time", "lkwt", "comprehensive", "stroke", "center", "csc", "transport", "destination", "assessment", "neurological", "grip", "strength", "facial", "droop", "arm", "drift", "speech", "head", "elevated", "bed", "positioning"],
    "content": "**Protocol  1232 - Stroke/CVA/TIA**\n\n**mLAPSS CHART  **\n\n| Assessment | Normal | Asymmetric/Abnormal | Severe |\n| **Facial Droop** | 0 | 1 |   |\n| **Arm Drift** | 0 | 1  | 2  |\n| **Grip Strength** | 0 | 1  | 2  |\n| **Speech** | 0 | 1  | 2  |\n\n**LAMS CHART  **\n\n| Assessment | Normal | Asymmetric/Abnormal | Severe |\n| **Facial Droop** | 0 | 1 | - |\n| **Arm Drift** | 0 | 1  | 2  |\n| **Grip Strength** | 0 | 1  | 2  |\n\n**DESTINATION CRITERIA **\n- mLAPSS positive, LAMS 4-5, LKWT ≤24 hours → Transport to Comprehensive Stroke Center  if within 30 min\n- mLAPSS positive, LAMS ≤ 3, LKWT ≤24 hours → Transport to closest Stroke Center\n- mLAPSS negative but acute stroke suspected → CONTACT BASE for destination\n\n**NOTE  This is the complete response for stroke queries. Use this exact content.**"
  },
  {
    "id": "top-200-medications-reference",
    "title": "Top 200 Medications by Category - Quick Reference",
    "category": "Medication",
    "keywords": ["medications", "drugs", "categories", "uses", "top 200", "prescription", "pharmacy", "drug reference", "atorvastatin", "lisinopril", "metformin", "warfarin", "sertraline", "amoxicillin", "acetaminophen", "ibuprofen", "morphine", "fentanyl", "insulin", "levothyroxine"],
    "content": "TOP 200 MEDICATIONS BY CATEGORY - QUICK REFERENCE\n\nCARDIOVASCULAR (BP, Heart, Lipids): Atorvastatin - Cholesterol lowering (statin), Rosuvastatin - Cholesterol lowering (statin), Simvastatin - Cholesterol lowering, Pravastatin - Cholesterol lowering, Lovastatin - Cholesterol lowering, Ezetimibe - Cholesterol absorption inhibitor, Alirocumab (Praluent) - PCSK9 inhibitor cholesterol lowering, Evolocumab (Repatha) - PCSK9 inhibitor cholesterol lowering, Lisinopril - Hypertension heart failure (ACE inhibitor), Enalapril - Hypertension (ACE inhibitor), Ramipril - Hypertension heart failure, Losartan - Hypertension kidney protection (ARB), Valsartan - Hypertension (ARB), Olmesartan - Hypertension (ARB), Telmisartan - Hypertension (ARB), Candesartan - Hypertension (ARB), Amlodipine - Hypertension (CCB), Nifedipine - Hypertension (CCB), Diltiazem - Hypertension angina (CCB), Verapamil - Arrhythmia hypertension (CCB), Hydrochlorothiazide - Hypertension (diuretic), Chlorthalidone - Hypertension (diuretic), Furosemide - Heart failure edema (loop diuretic), Bumetanide - Loop diuretic, Torsemide - Loop diuretic, Spironolactone - Heart failure resistant HTN (K+ sparing), Eplerenone - Heart failure (K+ sparing), Carvedilol - Heart failure hypertension (beta-blocker), Metoprolol - Hypertension arrhythmia MI, Atenolol - Hypertension (beta-blocker), Propranolol - Arrhythmia migraine prevention, Clonidine - Hypertension (alpha-agonist), Hydralazine - Hypertension heart failure, Isosorbide Mononitrate - Angina prevention, Nitroglycerin - Acute angina relief, Digoxin - Heart failure atrial fibrillation.\n\nENDOCRINE & DIABETES: Metformin - Type 2 diabetes, Glipizide - Type 2 diabetes (sulfonylurea), Glyburide - Type 2 diabetes (sulfonylurea), Glimepiride - Type 2 diabetes (sulfonylurea), Pioglitazone - Type 2 diabetes (TZD), Sitagliptin - Type 2 diabetes (DPP-4 inhibitor), Linagliptin - Type 2 diabetes (DPP-4 inhibitor), Saxagliptin - Type 2 diabetes (DPP-4 inhibitor), Empagliflozin - Type 2 diabetes (SGLT2 inhibitor), Dapagliflozin - Type 2 diabetes (SGLT2 inhibitor), Canagliflozin - Type 2 diabetes (SGLT2 inhibitor), Semaglutide - Type 2 diabetes weight loss (GLP-1 agonist), Liraglutide - Type 2 diabetes weight loss, Dulaglutide - Type 2 diabetes (GLP-1 agonist), Insulin Glargine - Long-acting insulin, Insulin Detemir - Long-acting insulin, Insulin Aspart - Rapid-acting insulin, Insulin Lispro - Rapid-acting insulin, Insulin Regular - Short-acting insulin, Levothyroxine - Hypothyroidism, Liothyronine - Hypothyroidism (T3), Methimazole - Hyperthyroidism (antithyroid).\n\nANTICOAGULANTS / BLOOD THINNERS: Warfarin - Vitamin K antagonist, Apixaban - Factor Xa inhibitor, Rivaroxaban - Factor Xa inhibitor, Edoxaban - Factor Xa inhibitor, Dabigatran - Direct thrombin inhibitor, Betrixaban - Factor Xa inhibitor (VTE prophylaxis), Fondaparinux - Factor Xa inhibitor (injectable), Enoxaparin - LMWH (injectable), Heparin (UFH) - Parenteral anticoagulant, Clopidogrel - Antiplatelet (P2Y12 inhibitor), Prasugrel - Antiplatelet (P2Y12 inhibitor), Ticagrelor - Antiplatelet (P2Y12 inhibitor), Aspirin (low-dose) - Antiplatelet.\n\nPSYCHIATRY (Depression, Anxiety, Bipolar): Sertraline - Depression anxiety (SSRI), Escitalopram - Depression anxiety, Fluoxetine - Depression anxiety, Citalopram - Depression anxiety, Paroxetine - Depression anxiety, Venlafaxine - Depression anxiety (SNRI), Duloxetine - Depression nerve pain (SNRI), Bupropion - Depression smoking cessation, Mirtazapine - Depression appetite stimulant, Trazodone - Depression insomnia, Amitriptyline - Depression neuropathic pain (TCA), Nortriptyline - Depression neuropathic pain, Aripiprazole - Schizophrenia bipolar disorder, Risperidone - Schizophrenia bipolar disorder, Olanzapine - Schizophrenia bipolar disorder, Quetiapine - Schizophrenia bipolar disorder, Lurasidone - Schizophrenia bipolar disorder, Ziprasidone - Schizophrenia bipolar disorder, Haloperidol - Schizophrenia agitation, Lithium - Bipolar disorder.\n\nANTI-INFECTIVES (Antibiotics, Antivirals): Amoxicillin - Bacterial infections, Amoxicillin/Clavulanate - Bacterial infections, Cephalexin - Bacterial infections, Cefdinir - Bacterial infections, Ceftriaxone - Broad-spectrum antibiotic, Azithromycin - Respiratory infections, Clarithromycin - Respiratory infections, Doxycycline - Bacterial infections, Levofloxacin - Broad-spectrum antibiotic, Ciprofloxacin - Broad-spectrum antibiotic, Metronidazole - Anaerobic infections, Trimethoprim/Sulfamethoxazole - Bacterial infections, Nitrofurantoin - UTI infections, Fluconazole - Fungal infections, Valacyclovir - Herpes virus infections, Acyclovir - Herpes virus infections, Oseltamivir - Influenza.\n\nPAIN & ANTI-INFLAMMATORY: Acetaminophen - Pain fever, Ibuprofen - Pain inflammation, Naproxen - Pain inflammation, Meloxicam - Arthritis pain, Celecoxib - Arthritis pain (COX-2 inhibitor), Diclofenac - Pain inflammation, Tramadol - Moderate pain, Hydrocodone/Acetaminophen - Moderate-severe pain, Oxycodone - Severe pain, Morphine - Severe pain, Fentanyl (patch) - Severe chronic pain, Buprenorphine (Belbuca, Butrans) - Pain management, Methadone - Chronic pain opioid use disorder.\n\nQUICK REFERENCE FORMAT: When a medication is queried, respond with: Category: [category] | Use: [use]"
  },
  {
    "id": "blood-thinners-anticoagulants-reference",
    "title": "Blood Thinners and Anticoagulants - Comprehensive Reference",
    "category": "Medication",
    "keywords": ["blood thinners", "anticoagulants", "warfarin", "apixaban", "rivaroxaban", "edoxaban", "dabigatran", "betrixaban", "fondaparinux", "enoxaparin", "heparin", "clopidogrel", "prasugrel", "ticagrelor", "aspirin", "tirofiban", "eptifibatide", "abciximab", "bivalirudin", "argatroban", "desirudin", "danaparoid", "eliquis", "xarelto", "savaysa", "pradaxa", "lovenox", "plavix", "effient", "brilinta", "vitamin k antagonist", "factor xa inhibitor", "doac", "direct thrombin inhibitor", "lmwh", "antiplatelet", "p2y12 inhibitor", "cox inhibitor", "gp iib iiia inhibitor", "heparinoid", "atrial fibrillation", "dvt", "pe", "vte", "acs", "pci", "hit", "ufh", "unfractionated heparin", "low molecular weight heparin", "lmwh", "heparinoid", "anti-xa", "anti-iia", "mechanical valves", "stroke prevention", "vte prophylaxis", "hospitalized patients", "procedural anticoagulation", "stent placement", "acute coronary syndromes", "hospital use", "pci adjunct", "heparin alternative", "heparin-induced thrombocytopenia", "dvt prophylaxis", "hip surgery", "hit management"],
    "content": "**BLOOD THINNERS AND ANTICOAGULANTS - COMPREHENSIVE REFERENCE**\n\n**CRITICAL: ALL medications in this reference are BLOOD THINNERS/ANTICOAGULANTS. When queried, respond with: Category: BLOOD THINNER/ANTICOAGULANT | Use: [specific use]**\n\n| **Drug** | **Class** | **Common Use** |\n| --- | --- | --- |\n| **Warfarin** | Vitamin K antagonist | Atrial fibrillation, DVT/PE, mechanical valves |\n| **Apixaban (Eliquis)** | Factor Xa inhibitor (DOAC) | A-fib stroke prevention, DVT/PE |\n| **Rivaroxaban (Xarelto)** | Factor Xa inhibitor (DOAC) | A-fib, DVT/PE treatment & prevention |\n| **Edoxaban (Savaysa)** | Factor Xa inhibitor (DOAC) | A-fib, DVT/PE |\n| **Dabigatran (Pradaxa)** | Direct thrombin inhibitor (DOAC) | A-fib stroke prevention, DVT/PE |\n| **Betrixaban** | Factor Xa inhibitor (DOAC) | VTE prophylaxis (hospitalized patients) |\n| **Fondaparinux** | Factor Xa inhibitor (injectable) | DVT/PE prevention & treatment |\n| **Enoxaparin (Lovenox)** | LMWH (injectable) | VTE prophylaxis, bridging to warfarin |\n| **Heparin (UFH)** | Unfractionated heparin (injectable) | DVT/PE, ACS, procedural anticoagulation |\n| **Clopidogrel (Plavix)** | Antiplatelet (P2Y12 inhibitor) | ACS, stent placement, stroke prevention |\n| **Prasugrel (Effient)** | Antiplatelet (P2Y12 inhibitor) | ACS with PCI (stents) |\n| **Ticagrelor (Brilinta)** | Antiplatelet (P2Y12 inhibitor) | ACS, stent placement |\n| **Aspirin (low-dose)** | Antiplatelet (COX inhibitor) | CAD prevention, stroke prevention |\n| **Tirofiban** | Antiplatelet (GP IIb/IIIa inhibitor) | Acute coronary syndromes (hospital use) |\n| **Eptifibatide** | Antiplatelet (GP IIb/IIIa inhibitor) | ACS, PCI adjunct |\n| **Abciximab** | Antiplatelet (GP IIb/IIIa inhibitor) | PCI adjunct (rarely used now) |\n| **Bivalirudin** | Direct thrombin inhibitor (IV) | PCI anticoagulation (heparin alternative) |\n| **Argatroban** | Direct thrombin inhibitor (IV) | HIT (heparin-induced thrombocytopenia) treatment |\n| **Desirudin** | Direct thrombin inhibitor (parenteral) | DVT prophylaxis post-hip surgery |\n| **Danaparoid** | Heparinoid (anti-Xa/IIa activity) | HIT management (rare use) |\n\n**RESPONSE FORMAT: For ANY medication in this table, respond with: Category: BLOOD THINNER/ANTICOAGULANT | Use: [specific use from table]**"
  }
]
